
Review

Preclinical evidence and therapeutic perspectives on carnosine for the treatment of neurodegenerative disorders

Saviana Antonella Barbati^{1,2}, Giuseppe Carota³, Konstantinos Partsinevelos³, Lucia Di Pietro³, Anna Privitera⁴, Vincenzo Cardaci⁵, Andrea Graziani¹, Renata Mangione^{1,2}, Giuseppe Lazzarino⁶, Barbara Tavazzi^{1,2}, Valentina Di Pietro⁷, Emiliano Maiani^{1,2}, Francesco Bellia³, Angela Maria Amorini³, Giacomo Lazzarino^{1,2}, Shahid Pervez Baba^{8,9} and Giuseppe Caruso^{1,2,*}

¹ Departmental Faculty of Medicine, UniCamillus—Saint Camillus International University of Health Sciences, Rome, Italy

² IRCCS San Camillo Hospital, Venice, Italy

³ Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy

⁴ Department of Biological, Geological and Environmental Science, University of Catania, Catania, Italy

⁵ Università Vita-Salute San Raffaele, Milano, Italy

⁶ LTA-Biotech srl, Paternò, Catania, Italy

⁷ School of Infection, Inflammation & Immunology, Department of Inflammation and Ageing, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom

⁸ Center for Cardiometabolic Science, Louisville, KY, USA

⁹ Department of Medicine, Christina Lee Brown Envirome Institute, University of Louisville, Louisville, KY, USA

*** Correspondence:** Email: giuseppe.caruso@unicamillus.org; Tel: +3906400640.

Abstract: Carnosine (β -alanyl-L-histidine) is an endogenous dipeptide widely distributed in mammalian tissues, especially skeletal and cardiac muscle cells, and, to a lesser extent, in the brain. While early interest in carnosine was given because of its role in muscle cell metabolism and athletic performance, it has more recently gained attention for its potential application in several chronic diseases. Specifically, brain aging and neurodegenerative disorders have received particular attention, as a marked reduction in carnosine levels has been described in these conditions. Carnosine exerts a wide range of biological activities, including antioxidant, anti-inflammatory, anti-glycation, metal-chelating, and neuroprotective properties. Mechanistically, it acts by inhibiting the production of advanced glycation end products (AGEs), buffering cellular pH, and regulating intracellular nitric

oxide signaling and mitochondrial function. Its safety profile, the lack of toxicity, and significant side effects support its application for long-term therapeutic use. In this review, we aim to recapitulate and discuss the effects, dosages, and administration routes of carnosine in preclinical *in vivo* models, with a particular focus on neurodegenerative disorders where it has been shown to reduce oxidative stress, suppress neuroinflammation, modulate protein aggregation, and preserve cognitive function, all key features of neurodegeneration. Despite promising findings, there are gaps in the knowledge on how carnosine affects synaptic plasticity, neuronal remodeling, and other processes that play a central role in the pathophysiology of neurodegenerative disorders. Additionally, clinical translation remains challenging due to inconsistencies across *in vivo* studies in terms of dosage, treatment duration, routes of administration, and disease models, which affect reproducibility and cross-study comparability. Therefore, while carnosine emerges as a multifunctional and well-tolerated molecule, further research is needed to clarify its therapeutic relevance in human diseases. In this review, we also address future perspectives and key methodological challenges that must be overcome to effectively translate carnosine's biological potential into clinical practice.

Keywords: carnosine; *in vivo* studies; animal models; Parkinson's disease; Alzheimer's disease; stroke; cellular and molecular mechanisms; carnosinemia

1. Introduction

Carnosine (β -alanyl-L-histidine) is an endogenous dipeptide first isolated in 1900 by Gulewitsch and Amiradzibi, who identified it in meat extracts and named it carnosine from the Latin *caro, carnis*, meaning "meat" [1]. Carnosine can be found throughout mammalian tissues, along with its analogs homocarnosine, anserine, and ophidine/balenine [2,3]. It is particularly abundant in skeletal and cardiac muscles (up to \sim 20 mM), while a lower but still significant concentration (millimolar order) is present in the brain [4]. Carnosine metabolism involves several enzymes that are responsible for its synthesis, modification, degradation, and transmembrane transport [3,5] (Figure 1).




Figure 1. Enzymes regulating carnosine metabolism. Carnosine is synthesized by carnosine synthase 1 (CARNS1) from histidine and β -alanine, the latter being produced by glutamic acid decarboxylase-like 1 (GADL1). Misincorporated products from CARNS1 are metabolized by the peptidase PM20D2. Carnosine degradation is carried out by two dipeptidases: CNDP1 and CNDP2. The methylation of carnosine to form anserine is catalyzed by carnosine N-methyltransferase. Carnosine transport is mediated by two transporters: The apical SLC15A2 and a basolateral carrier.

Carnosine is synthesized by carnosine synthase 1 (CARNS1) from the amino acids β -alanine (β -Ala) and L-histidine (L-His), both of which are available in the bloodstream. Of the two, β -Ala is produced in the liver, primarily through the degradation of uracil and thymine, or obtained from the diet, while L-His is an essential amino acid and must be provided entirely through dietary intake. Carnosine levels in human tissues and biological fluids are tightly regulated by two carnosinases, enzymes belonging to the M20 metalloprotease family, which catalyze its hydrolysis into β -Ala and L-His. These include the serum enzyme carnosine dipeptidase 1 (CNDP1) and the cytosolic/tissue enzyme carnosine dipeptidase 2 (CNDP2) [6–8]. Carnosine exerts a wide range of pleiotropic biological effects, acting not only as a neurotransmitter and cryoprotector in the nervous tissues, particularly in the olfactory bulb and cortex [9], but also as a molecule that regulate immune responses, cellular metabolism, and nitric oxide (NO) signaling [4]. In particular, carnosine is not considered a classic mediator; in fact, in the central olfactory structures it functions as a co-mediator, being in pre-synapses together with the excitatory mediator glutamate. Carnosine multimodal mechanism of action is also characterized by antioxidant [10], anti-inflammatory [11,12], and anti-aggregating [13] activities along with its ability to chelate heavy metals [14] and sequester reactive aldehydes, such as 4-hydroxynonenal and acrolein [15]. Initially, carnosine studies were mainly focused on skeletal muscle, where supplementation, particularly with carnosine or its precursor β -alanine, was shown to enhance athletic performance by improving muscle contractility and buffering lactic acidosis during intense physical activity. However, it soon became of great interest due to its additionally promising beneficial effects for human health [16,17]. One of the major reasons behind the

growing scientific interest in this dipeptide lies in its excellent safety profile. Both preclinical and clinical studies have confirmed that carnosine is non-toxic, well-tolerated, and free of known drug interactions or serious adverse effects, making it a suitable candidate for long-term therapeutic strategies [18]. Some clinical studies employing its precursor β -ala have instead shown some unwanted effects consisting in paresthesia [19] or enhanced pain perception [20]. Given the broad cellular functions, spanning multiple physiological cellular processes, further strengthens the view of carnosine as a versatile and possible therapeutic target for a wide spectrum of chronic pathological conditions [21,22], including neurodegenerative disorders [4]. Moreover, while *in vitro* studies provide crucial insights into the comprehension of the carnosine cellular and molecular mechanisms of action, animal preclinical models are essential to get the complexity of a living organism. In fact, *in vivo* systems enable a more complete evaluation of the efficacy, toxicity, and pharmacokinetics of the dipeptide, all aspects that cannot be fully addressed in a cell-based study. Furthermore, the more sophisticated genetic manipulation technique has enabled the development of animal models that closely resemble human pathological conditions, enabling the translational value of preclinical findings. Carnosine is a promising dipeptide, but its translation into clinical practice remains challenging due to significant “internal” heterogeneity related to the *in vivo* studies along with inconsistencies between the latter and clinical studies, the most important one regarding the use or not of anserine together with carnosine. These internal gaps are largely ascribable to the different types of experimental model used, the dosage administered, and the route of administration selected. In this review, we aim to (i) provide a comprehensive overview of the preclinical results obtained with carnosine administration on *in vivo* models; (ii) summarize the experimental models, dosages, protocols, and routes of administration employed; and (iii) analyze the effect of carnosine on brain with particular attention on neurodegenerative disorders. It is worth mentioning that all the studies described below were conducted using L-carnosine unless otherwise specified. Interestingly, though carnosine has consistently shown efficacy in reducing oxidative stress, neuroinflammation, and protein aggregation in neuropathological condition, there are critical knowledge gaps to be filled. Further investigation is needed to better understand carnosine effect and impact on cellular and molecular mechanisms that are central to neurodegenerative processes, such as synaptic plasticity, neuronal remodeling, and synaptic weakening, which underline neuronal dysfunction in central nervous system (CNS) disorders. Overall, the review emphasizes the urgent need for more standardized and translationally leaning studies to clarify carnosine’s true therapeutic potential in the context of human diseases, with a closer eye on neurodegenerative disorders. Finally, in the discussion, we explore future perspectives and the challenges that must be addressed to effectively translate preclinical success into clinical practice.

2. *In vivo* administration routes and animal models

In vivo carnosine studies encompass a wide range of animal models, dosing treatments, and delivery routes across pathological conditions. The studies included in Table 1 were identified through searches on PubMed and Google Scholar databases, covering the period from 2004 to 2025, using the “carnosine” in combination with one or more keywords, including “animal models”, “*in vivo*”, “systemic disorder”, and “neurodegenerative disorders.” The resulting studies, after a validity check, have been subsequently categorized according to year of publication, pathology, animal model, carnosine dose, administration route, and duration of the treatment. Table 1 and the discussion of the contents are structured to first address the effects of carnosine in non-neurological conditions, such as diabetes and pulmonary dysfunction, followed by a more in-depth analysis of neurological pathologies.

Table 1. *In vivo* carnosine studies: Treatments, doses, and delivery routes across pathological conditions.

Non-neurological pathologies						
Article	Pathology	Animal model	Carnosine dose (unless otherwise indicated)	Administration route	Duration	Note
Lee 2005 [23]	Diabetes	Three- to four-week-old male Balb/cA mice	0.5, 1 g/L	Oral (daily) in the drinking water	4 weeks	To induce diabetes, the mice were treated with streptozotocin (STZ) (40 mg/kg BW in 0.1 M citrate buffer, pH 4.5) i.p. for 5 consecutive days.
Tanida 2005 [24]	Renal sympathetic nerve activity (RSNA) in urethane-anesthetized rats	Male Sprague-Dawley (SD) rats, weighing ~350 g	0.01, 0.1, 1, 10, and 100 µg/0.1 ml saline	Intravenous (i.v.) injection	120 minutes	
Kurata 2006 [25]	RSNA and Ischemia/Reperfusion (I/R)-Induced Renal Injury	Male SD rats (280–320 g; 10 weeks of age)	Carnosine (1.5 and 15 nmol/rat i.v. or 1.5 and 5 pmol/rat i.c.v.) or L-histidine (5 pmol/rat i.c.v.) or N- α -Acetyl-L-carnosine [N-acetyl- β -alanyl-L-histidine] (5 pmol/rat i.c.v)	i.c.v.	45 minutes (RSNA); 24 hours (I/R-Induced Renal Injury)	Drugs were administered to ischemic-induced Acute Renal Failure (ARF) rats 5 minutes before the start of ischemia. A selective histamine H3 receptor antagonist, thioperamide (30 nmol/rat i.c.v.), which was given 10 minutes before the ischemia, eliminated the preventing effects by L-carnosine (15 nmol/rat i.v.) on ischemic ARF. In contrast, a selective H3

						receptor agonist, R-methylhistamine (5 pmol/rat i.c.v.), prevented the I/R-induced Renal Injury as well as L-carnosine (5 pmol/rat) did.
Cuzzocrea 2006 [26]	Bleomycin-induced lung injury	Male CD mice (25–35 g; Harlan Nossan)	150 mg/Kg	Oral (daily)	7 days	Carnosine administered 30 minutes after the bleomycin.
Mahmoud 2006 [27]	Hypercholesterolemic	Male newzeland white rabbits (2.5–3 kg)	50 mg/Kg	Oral (daily)	6 weeks	Comparative study between carnosine and fluvastatin.
Sauerhöfer 2007 [28]	Diabetes	Cg-m ^{+/+} Lepr db/J mice (line 000642; The Jackson Laboratory, ME). <u>Model 1:</u> Nondiabetic nontransgenic (db/wt) mice. <u>Model 2:</u> Diabetic nontransgenic (db/db) mice. <u>Model 3:</u> Diabetic transgenic db/db (db/db CN1+) mice. <u>Model 4:</u> hCN1 transgenic db/wt mice.	4 mmol/l L-carnosine	Oral in the drinking water (three times a week)	23 weeks (L-carnosine supplemented db/db mice gained significantly more weight throughout the observation period until 22 weeks of age compared with diabetic controls (db/db water))	In the experimental group of nontransgenic db/db mice was given drinking water supplemented with L-carnosine or water only (db/db water). L-carnosine-supplemented drinking water was replaced three times a week. Direct measurements of L-carnosine within the drinking bottles verified that l-carnosine was stable over a period of at least 5 days at room temperature (data not shown). Daily drinking

Fouad 2007 [29]	IR liver injury	Male SD rats, weighing 180–200 g	250 mg/kg	i.p.	7–14 days	volumes were determined. Pre-treatment with a single i.p. dose of carnosine, 30 minutes prior to the ischemic episode.
Kamei 2008 [30]	Diabetes	Male ICR 4-week-old mice (about 20 g)	L-carnosine (0.5 mmol/kg) Zinc-L-carnosine (0.25–1 mmol/kg)	Oral (daily)	8 weeks	Carnosine administered 1 day after the injection of STZ (200 mg/kg, i.v.), used to induce diabetes in animals.
Liu 2008 [31]	Ethanol-induced liver injury	chronic	Male Balb/cA mice, 3–4 weeks old (BW of 22.1 ± 0.5 g)	0.5, 1, 2 g/L	Oral in the drinking water	3 weeks
Mehmetçik 2008 [32]	Hepatotoxicity (thioacetamide-induced liver injury)		Female Wistar rats	250 mg/kg	i.p.	24 hours
Baykara 2009 [33]	I/R injury in the liver		Female Wistar albino rats, weighing 200–250 g	250 mg/kg	i.p.	4/5 hours
						Carnosine and melatonin (10 mg/kg) were administered i.p. 30 minutes before ischemia and immediately after the reperfusion.

						The liver was reperfused for 4 hours in the groups.
Yan 2009 [34]	Hepatotoxicity: acetaminophen-induced liver injury	Five- to 6-wk-old male Balb/cA mice	0.5, 1, or 2 g/L	Oral in the drinking water	4 weeks	After 4 weeks of treatment, mice were divided into 2 groups. One group was sacrificed, and the other group was treated by acetaminophen (APAP) intraperitoneally (i.p. 350 mg/kg body weight), and killed with carbon dioxide after 24 h.
Fouad 2009 [35]	Cadmium-induced acute hepatotoxicity	Male albino mice (25–30 g)	10 mg/kg	i.p. (daily)	4 days	Carnosine administered 3 consecutive days, starting 1 day before cadmium administration.
Kamal 2009 [36]	Physiological process: Effect of PEPT2 on the disposition of endogenous and exogenous carnosine	Gender- and weight-matched wild-type (Pept2 ⁺⁺) and null (Pept2 ^{-/-}) mice (99% C57BL/6 genetic background) 8 to 10 wk	1 nmol/g	i.v. bolus dose	Minutes	Pharmacokinetic studies.
Renner 2010 [37]	Human cancer therapy	Female nude mice Crl: CD [®] - 1-Foxn1 ^{nu}	500 µl carnosine (1 M) dissolved in NaCL- solution (0.7%), ph 7.4	i.p. (daily)	24 days	All injections were performed for 6 days with a 1-day break, starting again for 6 days.
Turkcu 2010 [38]	Ethanol-induced oxidative stress	Six-month-old male Wistar rats (250–300 g)	1 mg/kg	Oral (daily)	13 days	Carnosine was administered alone or as add-on to ethanol (EtOH). EtOH + CAR group:

						Carnosine was administered orally 10 minutes after the ethanol was injected i.p. at a dose of 2 g/kg/day.
						Carnosine was dissolved in phosphate-buffered saline solution.
Aydin 2010 [39]	Treatment on prooxidant-antioxidant balance	Young (5 months) and aged (22 months) male Wistar rats	250 mg/kg	i.p. (daily)	1 month	
Aydin 2010 [40]	Thioacetamide (TAA)-induced liver cirrhosis	Female Wistar rats (BW 160–200 g)	2 g/L	Oral (daily) in the drinking water	3 months	TAA plus carnosine group received 200 mg TAA/kg BW i.p. twice a week plus 2 g carnosine/L for 3 months.
Artun 2010 [41]	Ethanol-induced oxidative stress and hepatotoxicity	Female Wistar rats	2 g/L in drinking water	Oral (daily)	4 weeks	
Riedl 2011 [42]	Diabetic nephropathy (DN)	Male Wistar rats	1g/kg BW	Oral (daily)	3 months	L-carnosine was administrated after 3 months of diabetes and treatment (in Diabetic Wistar rats).
Aldini 2011 [43]	Dyslipidaemia and renal function in Zucker obese rats	Male Zucker obese (<i>fa/fa</i>) rats (ZK) and lean littermates (<i>Fa/Fa</i>) (LN) at 5 weeks of age.	The Zucker rats received a daily dose of L-CAR or D-CAR (30 mg/kg in drinking water). For the evaluation of the pharmacokinetic profile, L-CAR or D-CAR was	Oral (daily)	24 weeks	Approximately 3 days before treatment and while under anaesthesia, animals were fitted with a cannula implanted in the superior vena cava via the jugular vein.

			orally administered at a dose of 100 mg/kg to three male SD rats/test compound.			
Tsoi 2011 [44]	Stress-induced glucose metabolism disorder	Six-week-old male Kunming mice, weighing from 18 to 22 g	150 and 300 mg/kg	Oral/daily (carnosine was dissolved in distilled water)	7 days	
Mong 2011 [45]	Hepatic steatosis	Male 3-week-old C57BL/6 mice (16–18 g)	1 g/L	Oral (daily)	8 weeks	Water intake ml/mouse/day: Control diet 2.6 ± 1.2 (2.6 mg/d); high fat diet 5.9 ± 1.2 (6 mg/d).
Li 2012 [46]	Stress-evoked immunocompromise	Seven-week-old male Kunming and C57BL/6 mice	150 and 300 mg/kg B W	Oral (daily)	7 days	
Menini 2012 [47]	Atherosclerosis and renal disease	Adult (aged 6 weeks) female ApoE null mice (Charles River)	60 mg/kg BW in the drinking water	Oral (daily)	12 weeks	
Peters 2012 [48]	Diabetic nephropathy (DN)	Male C57BL/KsJm/Leptdb (db/db) mice	5 g/L in the drinking water	Oral (the estimated daily intake was 20 mg carnosine per day)	4 weeks	Treatment of <i>db/db</i> mice started at 8 weeks of age, before they had developed hyperglycemia and proteinuria.
Ansurudeen 2012 [49]	Diabetic wound healing	C57BL/KsJm/Leptdb (db/db) mice	100 mg/kg B W	i.p. (daily)	12 days	100 µL of carnosine (25 mg/mL in 60 % polyethylene glycol) was administered every day and was topically applied through the dressing every alternate day.
Barski 2013 [50]	Arteriosclerosis	Female ApoE-/ mice (19–23 g)	Octyl-D-carnosine	Oral (daily)	6 weeks	Water consumption of 2.5

			60 mg/kg/day			mL/mouse/day.
Everaert 2013 [51]	Muscle contractility and fatigue	Male Naval Medical Research Institute (NMRI) mice (45.9 ± 5.9 g BW)	0.1%, 0.5%, or 1.8%	Oral in the drinking water	8–12 weeks	
Sahin 2013 [52]	Septic shock	SD rats	250 mg/kg	i.p.	24 hours	Rats in the treatment group received a single I.P. of carnosine 60 minutes after cecal ligation-perforation.
Kalaz 2014 [53]	Oxidative stress and tissue damage induced by D-galactose in rat liver	Male Wistar rats (200–220 g)	250 mg/kg/daily; 5 days/week	i.p.	2 months	Rats received GAL (300 mg/kg) alone or together with CAR or TAU (2.5 % w/w; in rat chow)
Giriş 2014 [54]	Hepatic steatosis and oxidative stress	Male SD rats	2 g/L in drinking water	Oral (daily)	8 weeks	
Macarini 2014 [55]	Pathophysiological mechanisms including Impairment of electron transfer chain	Twenty-four male Wistar rats (250–300 g; age 30 days)	100 mg/kg of BW	i.p.	24 hours (in acute administration) or 5 days (in chronic administration)	Male Wistar rats were divided into acute and chronic treatment groups: In the first administration, the animals received a single dose of carnosine; in the second administration, the animals received a daily dose of the dipeptide administered for five days, and 1 hour after the last injection the rats were euthanized by decapitation.

Brown 2014 [56]	Atherosclerosis	Apo E-/- mice (50% C57BL/6, 50% 129SvJ) 5–9 weeks, 24–30 g	2 g/L	Oral (daily) (water available <i>ad libitum</i>)	20 weeks	Previous studies have revealed increases in plasma carnosine at 1.0 but not 0.5 g carnosine/L drinking water over 4 weeks.
Evran 2014 [57]	Isoproterenol (ISO)-induced myocardial infarction	SD male rats (300–400 g)	250 mg/kg/day	i.p.	2–12 days	Carnosine administered 30 minutes or 10 days prior to injection with ISO. The effects of carnosine treatment on these parameters were also investigated 24 hours after the last ISO injection.
Peters 2014 [58]	Diabetes	SD rats (350 to 420 g)	1 g/kg BW	Oral (daily)	24 weeks	
Bao 2015 [59]	N/A	Pigs (Landrace × Yorkshire) with an initial BW of 57.93 ± 3.14 kg	0.1% supplemental level in basal diet	Oral (diet, <i>ad libitum</i>)	~2 months (the experimental period is not stated, but it can be approximately estimated based on the results [total weight gain divided by daily weight gain]).	Comparative and combination study with alpha-lipoic acid (0.03%). L-carnosine supplementation induced weight gain, increased serum triiodothyronine, thyroxine levels, and decreased total cholesterol and triglycerides levels.
Stegen 2015 [60]	High-fat diet-induced metabolic stress	Old male Wistar rats	1.8% carnosine in their drinking water	Oral (daily) (water available <i>ad libitum</i>)	8 weeks	1.8% was chosen because Everaert et al. (2013) have

			(80 mmol/L) 1697 ± 175 mg/kg/day			shown that it results in a significant increase in carnosine (+57%) in extensor digitorum longus muscle in mice.
Forsberg 2015 [61]	Diabetes (glucose homeostasis)	<i>Db/db</i> mice (as a model of type 2 diabetes) and heterozygous non-diabetic mice, littermate as the control	5g/L	Oral in the drinking water	4 weeks	Since L-carnosine was reported to be stable in the water bottles over a period of minimum 5 days at room temperature, it was chosen to replace the water every 5 days.
Wu 2015 [62]	Physiological alterations including blood glucose, cardiovascular functions	Male Wistar rats (6 weeks of age and weighing ~160 g)	10 mg/kg	Orally (daily)	2 weeks	Rats were fed carnosine Car (for 2 weeks) before the reversal of light-dark cycle. Then rats were also subjected to a similar 12 hours experimental jet lag and sampled at 4 hours intervals on day 3 and day 5.
Menini 2015 [63]	Diabetes-induced atherosclerosis and renal disease	Six-week-old adult female Apoe-null mice were rendered diabetic by STZ and non-diabetic Apoe-null mice as controls	60 mg/kg BW D-carnosine-octylester (DCO) dissolved in the drinking water	Oral (daily)	20 weeks	Apoe-null mice were rendered diabetic by STZ and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from

						week 9 to 19 (DCO-Late). Non-diabetic Apoe-null mice served as controls.
Alsheblak 2016 [64]	Hepatic injury	Male SD rats	250 mg/kg; daily	i.p.	6 weeks	
Ahshin-Majd 2016 [65]	STZ-induced diabetic	Male albino Wistar rats, 8–10 weeks old (185–240 g)	50 and 100 mg/kg	i.p. (dissolved in normal saline)	7 weeks	The treatment of carnosine began 1 week after induction of diabetes using STZ.
Milewski 2016 [66]	TAA-induced liver failure	Adult male SD rats, weighing 250–280 g	His or Car (100 mg/kg)	i.p.	24 hours	L-histidine or carnosine were administrated 2 hours before TAA (i.p., 300 mg/kg 3 × in 24 hours intervals) injection into rats.
Kumral 2016 [67]	Doxorubicin (DOX)-induced toxicity	SD male rats that weighed 200–220 g	250 mg/kg	i.p.	12 days	Rats were treated with carnosine or carnosine + vitamin E (equals 200 mg kg ⁻¹ α-tocopherol; once every 3 days; intramuscularly) for 12 consecutive days.
Hasanein 2016 [68]	Lead acetate-induced hepatotoxicity	Adult male Wistar rats (8 weeks old, weighing 220–250 g)	10 mg/kg	Oral (daily)	8 weeks	
Hasanein 2015 [69]	Lead-induced oxidative stress and nephrotoxicity	Adult male Wistar rats weighing 220–250 g	10 mg/kg	Intragastrically (i.g.)	8 weeks	Animals received an aqueous solution of lead acetate (500 mg Pb/L in the

						drinking water) and/or carnosine.
Fouad 2017 [70]	Liver carcinogenesis	SD male rats (250–280 g)	10 mg/kg/day	i.p.	2 weeks	Carnosine was administered 5 days after trichloroacetic acid (TCA) treatment (500 mg/kg/day, p.o. for 5 days).
Sun 2017 [71]	Acute Lung Injury in Sepsis	Adult male albino Wistar strain rats (160–180 g)	25 mg/kg and 50 mg/kg	Oral	30 days	
Hasanein 2017 [14]	Ameliorating nickel-induced nephrotoxicity	Adult male Wistar rats weighing 220–250 g	10 mg/kg	i.g.	21 days	Animals received NiSO ₄ (20 mg/kg/day i.g.) and (or) carnosine and then were evaluated for biochemical, molecular, and histopathological alterations.
Albrecht 2017 [72]	DN	BTBR (Black and Tan, BRachyuric) <i>ob/ob</i> and <i>ob/ob</i> control mice	4 mM	Oral (daily)	18 weeks	Interestingly, carnosine-administered <i>ob/ob</i> mice showed a significantly lower daily water intake towards the end of the experimental period compared with <i>ob/ob</i> control mice.
Aydin 2017 [73]	STZ-induced diabetes	Male Wistar rats (3–4 months; 220–240 g)	250 mg/kg; five times a week	i.p.	4 weeks	Carnosine was administered after 8 weeks of high fat diet (60% of total calories from fat) and

						4 weeks after of STZ treatment (40 mg/kg) for a total 12-week experimental period.
Aydin 2017 [74]	Renal Function, Oxidation and Glycation Products in diabetic rats	Male Wistar rats (3–4 months; 220–240 g)	250 mg/kg; five times a week	i.p.	4 weeks	
Sahin 2018 [75]	Septic Shock	SD rats (weight, 200–300 g)	250 mg/kg (diluted into 5 mL saline)	i.p.	24 hours	Rats (in group 3) received an i.p. of carnosine 60 minutes following cecal ligation and puncture (CLP).
Iacobini 2018 [76]	The effect of FL-926-16 (a novel bioavailable carnosinase-resistant carnosine derivative) in the DN	C57BLKS/J ^{Lepr} male 6 - week-old diabetic <i>db/db</i> and control <i>db/m</i> mice	FL-926-16 (30 mg·kg ⁻¹ body weight)	Oral (daily) in the drinking water	From weeks 6 to 20 (prevention protocol) or from weeks 20 to 34 (regression protocol)	
Deng 2018 [77]	Oxidative DNA damage in bone marrow cells as a side effect of the anti-cancer alkylating agent cyclophosphamide (CTX)	Male Kun-Ming (KM) mice (18–22 g)	100 and 200 mg/kg	i.p. (after CTX treatment)	1, 5, and 10 days	
Abplanalp 2019 [78]	The deleterious effects of particulate matter exposure	Male C57BL/6 mice at 12 weeks of age	1 mg/mL	Oral (daily) (water available <i>ad libitum</i>)	6-hour exposure a day of a 9-day exposure regimen	Carnosine was administrated 1 week before the onset of exposure.
Liu 2020 [79]	CTX-induced bone marrow	Male C57BL/6J mice (6–8	1 g/kg/day	Oral (daily)	8, 12, and 16	

Zhao 2020 [80]	suppression prevention	weeks		(water available <i>ad libitum</i>)	weeks	
	Myocardial I/R injury	Adult male C57BL/6, wild type littermates (WT) and ATPGD1-transgenic (Tg) mice	- β -alanine (20 mg/mL) for adult male C57BL/6 mice (to increase intracellular levels of carnosine); - Carnosine (\pm 10 mg/mL) for WT mice	Oral (daily) in the drinking water	7 days	To evaluate the effect of elevated myocardial carnosine levels, these mice were subjected to coronary ligation for 30 minutes followed by 24 hours of reperfusion.
Everaert 2020 [81]	DN	Human CNDP1 TG mice were generated in the BTBR ^{WT/Ob} (Black and Tan, BRachyuric)	10 mM	Oral (daily) in the drinking water	20 weeks	Two interventions, aerobic exercise training and overexpression of the human carnosinase-1 (hCN1) enzyme, were tested.
Qiu 2020 [82]	Diabetic kidney disease (DKD)	Transgenic hCN1 TG BTBR ^{WT/Ob} and control BTBR ^{WT/Ob} mice	4 mM carnosine	Oral (daily) (water available <i>ad libitum</i>)	2 weeks	
Weigand 2020 [83]	Glucose homeostasis	11- and 55-week-old Cndp1-knockout (Cndp1-KO) and C57BL/6J wildtype controls mice	1 mg/mL	Carnosine substrate solution was added to 150 μ L sample supernatant to test carnosinase activity	0, 10, 20, and 40 minutes of incubation	To inhibit residual renal carnosine degrading activity in Cndp1-KO mice, this assay was repeated with an additionally 0.1 mmol/L bestatin added to the carnosine substrate solution [21].
Ommati 2020 [84]	Ifosfamide (IFO) nephrotoxicity	Male SD rats (weighing 200–250 g)	250 and 500 mg/kg	i.p.	5 days	Rats were treated with IFO (50 mg/kg, i.p) alone or in

						combination with carnosine.
Yaqub 2021 [85]	Prepartum (ewes)	Yankasa ewes (average weight of 23.8 ± 1.21 kg and an age of 2–3 years)	100 mg/kg	Oral (daily) (water available <i>ad libitum</i>)	3 weeks	The administration started from the last 3 weeks prepartum up to the last day of gestation (between 129 ± 2 and 150 ± 2 days).
Stefani 2021 [86]	Myocardial infarction	Male Wistar rats [weighing between 220 and 300 g (approximately 70–90 days of age)]	β -alanine and L-histidine orally (250 mg/kg per day)	Oral (daily) (via gavage in 1.0 mL of distilled water)	8 weeks	Animals were submitted to myocardial infarction. Supplementation occurred at the same time of the day in each training session.
Riger 2021 [87]	Initial stage of non-alcoholic fatty liver disease	Male Wistar rats with initial BW 150 ± 10 g within 8 weeks	High-calorie choline-deficient diet (HCCDD) with the addition of carnosine (75 mg/kg BW)	Oral (daily)	N/A	
Gonçalves 2021 [88]	Cardiac dysfunction (the impairment of contractile function)	Male Wistar CARNs1 ^{−/−} rats (knockout, 4 months-old) and their wild type (WT) controls	1.8% in the drinking water	Oral (daily)	12 weeks	
Schwank-Xu 2021 [89]	Hepatic Steatosis in Diabetic Conditions	12-week-old <i>db/db</i> mouse model of type 2 diabetes mellitus (BKS.Cg-Dock7m ^{+/+} LeprdbJ) and heterozygote normoglycemic C57BLKS/J littermates (C57B)	20 mM	Oral in the drinking water	10 days	
Nooh 2021 [90]	Infertility related to chemotherapeutic agents		250 mg/kg/day	i.p.	5 weeks	Group I was the control. Group II received

Zhu 2021 [91]	DN	Male C57BL/6J mice (6–8 weeks of age) STZ-induced diabetes	1000 mg/kg	Drinking water	12 weeks	carnosine; Group III received CHOP: CTX (27 mg/kg/cycle), DOX (1.8 mg/kg/cycle), and vincristine (0.05 mg/kg /cycle) by i.p. plus oral prednisone (1.47 mg kg ⁻¹ day ⁻¹ /cycle). Group IV received carnosine plus CHOP.
Busa 2022 [92]	Knee osteoarthritis (OA)	Male Wistar rats (8 weeks old)	0.5 and 1.0 g/kg/day	Oral administration	12 weeks	Experimental groups: control group, control + carnosine group, STZ group, and STZ + carnosine group.
Rodríguez-Niño 2022 [93]	Diabetic kidney disease (DKD)	Wild-type, diabetic BTBR ^{wt/ob} , 6-week old male mice	45 mg/kg	Drinking water	18 weeks	Mice were either subjected to carnosine supplementation or genetically manipulated by overexpressing hCN1
Park 2022 [94]	Idiopathic Pulmonary fibrosis (IPF)	C57BL/6 mice (8 weeks/male, 22–25 g)	150 mg/kg	Oral administration	2 weeks	The mice were i.t. injected with BLM (3 mg/kg) and L-carnosine (150 mg/kg) was orally administrated for 2 weeks.
Zharikov 2022 [95]	Urate nephrolithiasis	Male Wistar rats	15 mg/kg	i.g.	10 days	
Ommati 2023 [96]	Cholestasis-induced injury	Male SD rats (250 ± 20 g)	100 and 500 mg/kg	i.p.	28 days	Bile duct ligation (BDL) to

Zhang 2023 [97]	DN	C57BL/6 J mice, 6–8 weeks of age	1000 mg/kg	Oral in the drinking water	16 weeks	induce cholestasis.
Rathor 2023 [98]	Skeletal muscle protein loss	Male SD rats (BW: 200 ± 20 g)	50 mg/kg	Oral route using a gastric cannula once daily	3 days	Mice were injected intraperitoneally with 50 mg/kg of STZ daily for 5 days to induce diabetes. Fer-1 (delivered i.p.) 5 mg/kg; carnosine delivered at 1 g/kg dose of drinking water.
Luo 2023 [99]	Acute kidney injury	Male C57BL/6 J mice (age, 6–8 weeks; weight, 18–22 g)	2g/kg	i.p.	3 days before and 1 day after cisplatin injection	Efficacy of nutritional supplementation of β -alanine (450 mg/kg) and L-carnosine (50 mg/kg) in ameliorating the hypobaric hypoxia-induced muscle protein loss.
Berdaweeil 2023 [100]	Obesity-related cardiomyopathy	Wild-type (WT) and GPx4 ^{+/−} male mice	(80 mM)	Oral (daily) in the drinking water	9 weeks starting from the 7th week after beginning the diet	Pyroptosis is involved in cisplatin-induced acute kidney injury.
Moreto 2023 [101]	Nonalcoholic fatty liver disease (NAFLD)	Male Wistar rats (8 weeks old)	250 mg/ kg/day	i.p.	5 weeks	The administration of L-carnosine reversed liver

						steatosis. The protein profiles of NAFLD liver group and carnosine NAFLD liver group were evaluated by label - free proteomics approach (2531 proteins were identified).
Grandini 2024 [102]	Metabolic dysfunction-associated steatotic liver disease (MASLD)	Male Wistar rats	250 mg/kg	i.p.	4 weeks	
D'Amato 2024 [103]	Chronic obstructive pulmonary disease (COPD)	C57BL/6J mice	10, 50, or 100 mg/kg/day	Inhaled	12 days	The mice were exposed to 3R4F reference cigarettes with filters removed for approximately 60 min, twice daily, 4 hours apart, for 12 consecutive days.
Drenjančević 2024 [104]	Oxidative stress	SD rats (8–10 weeks old, both sexes)	150 mg/kg/day	Oral administration (gavage)	7 days	High-salt (HS)-intake-related increase of oxidative stress. Experimental groups: CTRL (control group, 0.4% NaCl), HS group (rats fed 4% NaCl in the rat chow for 7 days), CTRL + carnosine group (rats administered oral carnosine supplementation, 150 mg/kg/day for 7 days)

						by oral gavage), and HS + carnosine group (rats fed HS diet and receiving oral carnosine supplementation).
Xu 2025 [105]	Focal segmental glomerulosclerosis (FSGS)	WT and TGRNeph-hAT1 transgenic rats with sex-dependent FSGS	4 nM	Oral (daily) in the drinking water	20 weeks	Carnosine supplementation ameliorated glomerular hypertrophy.
Meng 2025 [106]	N/A	3-month-old male crossbred lambs (Dorper ♂ × Small Tail Han ♀) with an average BW of 30 ± 5 kg	400 mg/kg	Oral (diet)	60 days	Lambs were randomly divided into two groups. Animals in the control group were fed only the basal diet. In the experimental L-carnosine group, L-carnosine was added to the basal diet.
Li 2025 [107]	Oxidative stress	Zebrafish larvae, chick embryos	Zebrafish larvae: 0.1, 0.5, 1.0, 1.5, and 2.0 mM. Chicken embryos: 2.5, 5 and 7.5 μ mol.	Zebrafish larvae: Incubation in 48-well plates. Chicken embryos: Injection.	Zebrafish larvae: 5 days. Chicken embryos: 12 days.	

Neurological pathologies

Article	Pathology	Animal model	Carnosine dose (unless otherwise indicated)	Administration route	Duration	Note
Tomonaga 2004 [108]	Carnosine effects: inhibited food intake and hypoactivity	Day-old male chicks (Julia strain)	3.2 and 6.4 μ mol	Intracerebroventricular (i.c.v.) injection	30, 60, 120, and 240 min	<u>Experiment 1:</u> Chicks (5-day-old) were injected carnosine (3.2 and 6.4 mol). <u>Experiment 2:</u> Chicks (6-

						day-old) were injected carnosine (6.4 mol)
						<u>Experiment 3:</u> Carnosine (0.8, 3.2 and 6.4 mol).
Tomonaga 2005 [109]	Carnosine effects: hyperactivity	5 or 6 days-old male chicks (Julia strain)	3.2 μ mol	i.c.v.	5, 10, and 15 min	iNOS inhibitors were also used.
						<u>Experiment 1:</u> Chicks were injected with carnosine plus L-NAME (400 nmol).
						<u>Experiment 2:</u> Carnosine (3.2 μ mol) plus L-NAME (200 or 400 nmol).
						<u>Experiment 3:</u> Carnosine (3.2 μ mol) plus D-NAME (400 nmol).
						<u>Experiment 4:</u> Carnosine (3.2 μ mol) plus L-NIL (400 nmol).
Zemke 2005 [110]	Mouse model of stroke	Male C57BL/6J mice	100 mg/kg and 500 mg/kg carnosine	Intraperitoneal (i.p.) injection	24 hours	Administered by intraperitoneal injection to male C57BL/6J mice 30 minutes prior to permanent occlusion of the middle cerebral artery.
Fedorova 2005 [111]	Prenatal hypoxia	Male and female 22 and 30-day-old rats	100 μ g/kg body weight (BW)	Oral (daily) in the drinking water	35 days	
Dobrota 2005 [112]	Ischemic injury (after-)	Model 1: Wistar rats (280–300	100 mg/kg BW	i.p.	7–14 days	<u>Model 1:</u> Modification to

	stroke-effect)	g)				the 4-vessel occlusion model (16) was made, and animals were exposed to 3-vessel occlusions (both common carotid arteries and the left arteria vertebralis) for 15 min.
		Model 2: Mongolian gerbils (65–75 g)				<u>Model 2:</u> Two-vessel occlusion (left and right arteria carotis communis) producing brain ischemia was followed by long-term reperfusion in this animal group.
Jin 2005 [113]	Amygdaloid-kindled seizures	Male SD rats (220–300 g)	(500, 1000, and 1500 mg/kg)	i.p.	0.5, 1, 2, and 4 hours	The protective effect of carnosine (1500 mg/kg) was completely antagonized by histamine H1-antagonists pyrilamine (2, 5 mg/kg, i.p.) and diphenhydramine (5, 10 mg/kg, i.p.) but not by histamine H2-antagonist zolantidine even at a high dose of 10 mg/kg.
Wu 2006 [114]	Pentylenetetrazole-induced kindled	Male SD rats (220–300 g)	200, 500 mg/kg	i.p.	30 min	Carnosine was injected 2 hours before PTZ

						treatment. Chemical kindling was elicited by repeated intraperitoneal injection of PTZ (35 mg/kg) once every 48 hours until the occurrence of Stage 4–5 seizures, and the seizure activity of kindling was recorded for 30 min.
Tsuneyoshi 2007 [115]	N/A	5- or 6-old-day male chicks (Julia strain)	2.8 μ mol of carnosine	i.c.v.	10 min	Comparative study between carnosine and other β -alanyl dipeptides.
Rajanikant 2007 [116]	Neuronal damage, infarct formation, endogenous antioxidant status, matrix metalloproteinase activity.	Male C57BL/6 mice (mouse model of permanent focal cerebral ischemia)	L-carnosine was dissolved in 9g/L sterile saline (100 mg/mL). 100, 500, and 1000 mg/kg administered 30 minutes before ischemia, or 1000 mg/kg administered 2 or 4 hours after ischemia supplemented by doses of 500 mg/kg every 6 hours, or 1000 mg/kg administered 30 minutes before ischemia supplemented by doses of 500 mg/kg every 6 hours.	i.p.	24 hours	Carnosine significantly decreased infarct size and neuronal damage when administered at time points both before and after the induction of ischemia.

Zhu 2007 [117]	Pentylenetetrazol-induced seizures	HDC-KO (histidine decarboxylase-deficient) and its WT (C57BL/6 strain) male mice	200, 500 or 1000 mg/kg	i.p.	4 hours	Carnosine was injected 1 hour before PTZ injection. The effects of carnosine (500 mg/kg) were time-dependent and reached a peak at 1 h.
Tanida 2007 [118]	Effects of injection of L-carnosine on sympathetic nerve activity	Male Wister rats, (300–350 g)	0.01, 0.1, 1, 10 and 100 µg	Intralateral cerebral ventricular (LCV) injection	120 min	
Tomonaga 2008 [119]	Depression (carnosine-induced antidepressant-like activity)	Male Wistar rats (six weeks old)	1.4 mmol/kg → 316,722 mg of carnosine/kg	Oral (10 ml CBX)	240 min	
Min 2008 [120]	Permanent focal ischemia	C57BL/6 mice (22–27 g)	Carnosine 1000 mg/kg or 1000 mg/kg N-acetyl carnosine	i.p.	1 day	Administered to mice 30 minutes before induction of permanent middle cerebral artery occlusion (MCAO).
Derave 2008 [121]	Senescence	Male SAMP8/Ta (senescence-accelerated mice prone)	100 mg/kg BW	Oral in the drinking water	50 weeks (from 10 to 60 weeks of age)	Mice were investigated at 10, 25, or 60 weeks of age.
Kozan 2008 [122]	Epileptiform activity	Epilepsy model in Wistar rats	125, 250, 500, and 1000 mg/kg	i.p.	90 min	30 minutes after penicillin injection, the doses of 125, 250, 500, and 1000 mg/kg of carnosine were administered i.p., and 90 minutes before penicillin injection, a dose of 500 mg/kg carnosine were

Pekcetin 2009 [123]	Transient cerebral ischemia	Female Wistar rats weighing between 200–250 g	250 mg/kg	i.p.	24 hours or 1 week	administered i.p. Transient ischemia was induced by occlusion of right common carotid artery of rats for 30 minutes and reperfusion for 24 hours or 1 week. Carnosine or saline solution were administered 30 minutes prior to experiment.
Feng 2009 [124]	Neuronal excitation and inhibition	Adult SD rats (200–350 g)	25, 50, and 100 mmol/L	Oral	20–30 min	To identify the relatively quick effects and slow effects separately, the PS (population spikes) responses during the first 5 minutes and late 20–30 minutes periods following the application of carnosine were evaluated.
Aydin 2010 [125]	Aging process	Young (5 months) and aged (22 months) male Wistar rats	250 mg/kg	i.p. (daily)	1 month	
Shen 2010 [126]	Permanent cerebral ischemia	Wild-type (WT) and HDC-KO male mice (C57BL/6 strain) (22–30 g)	250–500–750 mg/kg [Carnosine was dissolved in 9 g/L sterile saline (100 mg/ml)]	i.p. (daily)	24 hours	Carnosine was administered 30 minutes before ischemia.
Tsai 2010 [127]	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)	Three- to four-week-old male C57BL/6 mice (25 g)	0.5, 1, or 2 g/L in water (Water Intake 2	Oral (daily) (water available <i>ad libitum</i>)	4 weeks	After 4 weeks of care with carnosine, mice were

		treated mice	mL/mouse/day)		treated by daily subcutaneous injection of vehicle saline or MPTP (24mg/kg) for 6 consecutive days.
Zhang 2011 [128]	Hypoxia-ischemia	SD rat pups of either sex that weighed between 12 and 18 g	250 mg/kg	i.p.	24 hours
					Hypoxia-ischemia was induced in rats on postnatal day 7 (P7). Carnosine was administered 30 minutes prior to hypoxia-ischemia induction.
Di Paola 2011 [129]	Acute spinal cord injury (SCI)	Male Adult CD1 mice (25–30 g)	150 mg/kg D-carnosine/L-carnosine	i.p.	24 hours
					L-carnosine and D-carnosine were administrated 1 hour and 6 hours after SCI.
Corona 2011 [130]	Alzheimer's disease	One month old male 3xTg-AD mice	10 mM	Oral (daily)	11–13 months
Faddah 2012 [131]	Brain damage [traumatic brain injury (TBI)]	Male Wistar albino rats weighing 40 to 60 g (forty days old)	200 mg/kg	i.p. (daily)	7 days
					Carnosine was administered for 7 consecutive days following TBI.
Ma 2012 [132]	Subcortical ischemic vascular dementia	Eight-week-old wild-type (WT, C57BL/6 strain) and HDC-KO male mice weighing 22–30 g	200 mg/kg	i.p. (carnosine was dissolved in sterile saline)	32 days
					C57BL/6 mice were subjected to permanent occlusion of the right unilateral common carotid arteries (rUCCAO) and treated with carnosine or

						histidine (200 or 500 mg/kg) that were administered 30 minutes before surgery and every other day until the mice were sacrificed.
Ma 2012 [133]	Subcortical ischemic vascular dementia	Eight-week-old wild-type (WT, C57BL/6 strain) and HDC-KO male mice weighing 22–30 g	100, 200 or 500 mg/kg	i.p.	37 days	Adult male WT mice received rUCCAO and were administered with saline, carnosine, or histidine (200 or 500 mg/kg), 30 minutes before surgery and every other day until the mice were sacrificed.
Çoban 2013 [134]	Oxidative stress in some tissues of aged rats	Young (5 months) and aged (22 months) male Wistar rats	250 mg/kg	i.p.; 5 days per week	2 months	It investigated the effects of CAR + vitE and betaine treatments on oxidative and antioxidative status in liver, heart and brain tissues of aged rats.
Herculano 2013 [135]	Alzheimer's disease	B6C3-Tg (A β PP swe/PSEN1dE9) 85Dbo/J AD model animals. [These animals express the Swedish variation of the phenotype, presenting both a chimeric human A β PP transgene	5 mg/kg	Oral in the drinking water (daily)	6 weeks	The treatment with carnosine was given a steady dosage of carnosine diluted in de-ionized autoclaved drinking water at the concentration of 1 g/L. This treatment began

		(Mo/HuApp695swe) and human PS1 transgene (missing exon 9)].				2 weeks after the initial feeding with HFD and kept until the end of the experiments.
Wang 2013 [136]	Acute focal cerebral ischemia	SD rats (250–300g)	500, 750 and 1000 mg/kg	i.p. (30 minutes before operation and every 6h thereafter)	12, 24 and 72 hours	The study included 2 stages: 1) Multiple doses of L-carnosine and 2) a single dose of L-carnosine.
Bae 2013 [137]	Ischemic brain damage	Adult male SD rats weighing 250 to 300 g	100, 500, 1000, or 2000 mg/kg B W	i.v. bolus injection	24 hours	Saline, carnosine, or histidine (1000 mg/kg B W) were administered over 3 minutes into the lateral tail vein at 30 minutes prior to the occlusion of the middle cerebral artery. Blood samples were drawn from a femoral vein catheter before administration and at 15 min, 1 h, 3 h, 6 h, 12 h, and 24 h post-administration of carnosine.
Bae 2013 [138]	Ischemic stroke	Adult male SD rats	(500 to 2000 mg/kg)	i.v.	14 days	
Park 2014 [139]	Early stage of rodent stroke model	Rats. N.I.	100, 250, and 500 mg/kg	i.p.	2 hours	Rats with vehicle and carnosine treated groups were administered by i.p. injection 30 minutes before

Zhang 2014 [140]	Hypoxia-ischemia	Postnatal day 7 SD rats	250mg/kg	i.p.	72 hours	surgery. Hypoxia-ischemia was induced in rats on postnatal days 7–9 (P7–9). Carnosine was administered at 0 h, 24 h, and 48 h after hypoxia-ischemia was induced.
Ji 2014 [141]	I/R injury	C57BL/6 J mice, 3 months of age (20–25 g in weight)	1000 mg/kg	i.p.	2 weeks	L-Carnosine was administered to mice 30 minutes before induction of retinal ischemia. Retinal ischemia was induced by constant elevation of intraocular pressure (100–110 mmHg) for 60 minutes in C57BL/6 J mice pretreated with carnosine or saline.
Inozemtsev 2014 [142]	Effects of carnosine on learning and memory of animals with negative reinforcement with an electric pain stress.	White rats weighing 250–300 g	100 mg/kg	i.p.	8 days	The animals of the experimental group were i.p. injected with carnosine 1 hour prior to each experiment.
Albayrak 2015 [143]	Acute SCI	SD rats (280–300 g)	150 mg/kg at the first hour and then at 6 hours dose regimen	i.p. (150 mg/kg at the first hour and then at 6 hours dose regimen)	24 hours	

Dai 2015 [144]	Febrile seizures	WT and HDC-KO C57BL/6J mice pups	100, 200, 500 mg/kg	i.p. (1 hour before hyperthermia)	Hours (not specified)	
Macedo 2015 [145]	Various aspects of brain bioenergetics (respiratory chain complexes and citric acid cycle enzyme activities)	Male Wistar rats (80–100 g)	100 mg/kg	i.p. (single dose)	24 hours	
Russo 2015 [146]	Retinal ischemic injury	Adult male Wistar rats (280–330 g)	0.036 µmol/eye. (L-carnosine was prepared in sterile water at 100 mM concentrations)	Intravitreal injection	1 hour of reperfusion/7 days following the insult.	L-carnosine administration, alone or in combination with homotaurine (0.05 µmol/eye), was performed 1 h before and following the 50 minutes of ischemia. The duration of the injection (3 µL/eye) was 3 minutes in all instances.
Zhang 2015 [147]	Subarachnoid hemorrhage (SAH)-induced early brain injury (EBI)	Male SD rats (weighing 280–350 g)	(0.1 mL, 1000 mg/kg)	i.p. (daily)	48 hours	
Afshin-Majd 2015 [148]	Parkinson's disease	Adult male Wistar rats, weighing 230–280 g	250 mg/kg twice at an interval of 24 h	i.p. (twice at an interval of 24 h)	1 week	Carnosine was administered two times a day before the surgery, with the last injection being 1 h presurgery.
Aydin 2016 [149]	D-galactose (GAL)-treated model	Male Wistar rats (200–220 g)	250 mg/kg/daily; 5 days per week	i.p.	2 months	Rats received GAL (300 mg/kg) alone or together with carnosine or taurine (2.5 % w/w; in rat chow).

Ma 2016 [150]	White matter damage caused by subcortical ischemic injury	Male C57BL/6 mice (specific-pathogen-free/viral-antibody-free), 8-weeks-old, weighing 22–30 g	200, 500 or 750 mg/kg	i.p.	37 days	The animals were treated with carnosine by i.p. 30 minutes before injury and every other day after injury. However, carnosine at the higher dose of 750 mg/kg did not have the same effects as the 200 and 500 mg/kg doses.
El-Baky 2016 [151]	Closed Head Injury (CHI)	30-day-old male Wistar albino rats weighing 50–70 g	200 mg/kg	i.p.	7 days	Carnosine was administered immediately after truma, and for a period of 7 days following CHI.
Banerjee and Poddar 2016 [152]	Aging	Male albino Wistar strain rats	2.0 µg/kg/day	Intrathecally (i.t.)	21 days	
Al-Rasheed 2016 [153]	Hypoxic Rat Model	Wistar adult male albino rats weighing 170–200 g	250 mg/kg BW	i.p. as a single dose	25 hours	Carnosine was administered 24 hours before NaNO ₂ injection, and after one hour, the rats were sacrificed.
Kaneko 2017 [154]	Alzheimer disease	B6C3-Tg (APPswe/PSEN1dE9) 85Dbo/J AD-model mice	Anserine at 2.0 g/L (equivalent to 10 mg/mouse)	Oral (daily) (water available <i>ad libitum</i>)	8 weeks	
Zhao 2017 [155]	Salsolinol-induced Parkinson's disease	Male albino rats (weighing 180–200 g)	50 or 100 µg/mL	Oral	72 hours	Administration of 50 µg salsolinol + 50 µg carnosine or 100 µg salsolinol + 100 µg

						carnosine.
Keskin 2017 [156]	I/R injury	SD rats (250–300 g)	250 mg/kg	i.p. (10 minutes before completion of the ischemia period)	Minutes	
Stvolinsky 2017 [157]	Focal cerebral ischemia-reperfusion	Wistar rats	150 mg/kg of body mass	Oral administration (daily)	7 days	A focal ischemia in Wistar rats induced by the 60 min-occlusion of the middle cerebral artery with the following 24 h-reperfusion was used. Animals received carnosine mixed with ration in a daily dose for 7 days before surgery.
Xie 2017 [158]	Intracerebral hemorrhage (Oxidative Stress and Apoptosis)	Male SD rats (weighing 270–300 g, 12 weeks old)	1000 mg/kg	i.p.	72 hours	
Aydin 2018 [159]	Oxidative stress and Advanced Glycation End products (AGE) in GAL-induced aging	Male Wistar rats (200–220 g)	250 mg/kg/daily, 5 days per week	i.p.	2 months	
Devyatov 2018 [160]	Focal cerebral I/R	Wistar rats	150 mg/kg	Oral administration (daily)	7 days	Animals received carnosine for 7 days before the temporary occlusion of the middle cerebral artery (MCA), performed for 60 min. At 24 hours after the onset of ischemia, the effect of carnosine on the

						area of the necrotic core was evaluated in animals.
Fedorova 2018 [161]	Focal Ischemia	Male Wistar rats (age 12–14 weeks)	50 and 500 mg/kg	i.p.	24 hours	Carnosine was administered intraperitoneally according to the following scheme: 15 minutes after surgery animals received half of the experimental dose of carnosine, the other half was administered 2 hours and 15 minutes after surgery.
Wang 2018 [162]	Cerebral ischemia injury	Male SD rats (age, 10–12 weeks; weight, 280–320 g)	180 mg (in rats with BW of 300 g)	Oral gavage (daily)	7 days	The researchers aimed to determine the mechanism of the protective effect of beef decoction (BD) with carnosine against it. The carnosine content in BD was 36 mg/ml.
Barca 2018 [163]	Diabetic (pancreas and brain of STZ-Treated Mice)	Inbred male C57BL/6JB6 mice (12 weeks old)	1 g/L (in sterile deionized H ₂ O)	Oral (daily) in the drinking water	2 weeks	Carnosine detection in the pancreas and brains of mice that underwent STZ treatments.
Qi 2018 [164]	Brain oxidative damage in a pentylenetetrazole-induced epilepsy model	Female albino rats weighing 220–240 g	L-Homocarnosine (1mM); L-Carnosine (1mM)	Orally	45 days	This study investigated the protective effect of L-homocarnosine, L-carnosine, and anserine

						(HCA) on seizure-induced brain injuries.
Tiwari 2018 [165]	Vascular dementia	Male and Female Wistar rats weighing 200–300 g	200 and 400 mg/kg	i.p. (daily)	From 6 th to 9 th day	Donepezil and Carnosine were administered i.p. in sterile saline.
Colín-Barenque 2018 [166]	Impairment of olfactory function (such as Parkinson's and Alzheimer's diseases)	CD-1 male mice weighing 35 ± 2 g (2 months of age)	1 mg/kg	Oral (daily)	4 weeks	Carnosine treatment: Vanadium pentoxide (V ₂ O ₅) inhalation plus orally administered carnosine simultaneously and orally administered carnosine.
Bermúdez 2018 [167]	Parkinson's disease (oxidative stress and mitochondrial dysfunction)	Two months old WT and Thy1-aSyn mice	<ul style="list-style-type: none"> ▪ 2 mg/day for intranasal (IN) ▪ 50 mg/day based on water consumption 	IN or oral (daily)	2 months	Carnosine was applied in 10 µL of sterile dd H ₂ O.
Bermúdez 2019 [168]	Parkinson's Disease	Thy1-aSyn (TG) mice	2 mg/day (2 mg in 10 µL, which is near the limit of solubility and is without adverse effects)	IN	2 months	L-carnosine (>98%) was obtained from Acros Organics via Thermo Fisher (Morris, NJ, USA).
Jain 2020 [169]	Ischemic strokes	6 to 8-week old male C57bl/6J (20–25 g)	L- and D-carnosine (100, 500 or 1000 mg/kg)	i.p.	48 hours	To determine the relative cerebroprotective potential of D- and L-carnosine in transient focal ischemic damage, MCAO was induced for 60 min. The

						efficacy of both L- and D-carnosine were also tested when administered intravenously 2 hours post-transient-MCAO.
Dai 2020 [170]	Aging	Three-month-old male senescence-accelerated mouse prone 8 (SAMP8) mice	Carnosine 100 or 200 mg/kg/day	i.g.	6 weeks	
Ommani 2020 [171]	Mn-induced neurotoxicity	Male C57BL/6 mice	10, 50 and 100 mg/kg	i.p.	8 days	Mice received Mn (100 mg/kg, s.c) alone and/or in combination with carnosine.
Virdi 2020 [172]	Cerebral ischemia (ischemic postconditioning)	Albino mice of either sex (20–25 g)	500 mg/kg	i.p. (carnosine was dissolved in distilled water)	24 hours	
Devyatov 2020 [173]	Focal Ischemia	Wistar rats	150 mg/kg	Oral administration (daily)	7 days	The animals received hesperetin (50 mg/kg) and carnosine included in the diet of daily doses for 7 days before ischemia induction.
Attia 2020 [174]	Hemic hypoxia	Fifty Wistar adult male albino rats weighing 170–200 g	250 mg/kg	i.p.	26 hours	Hypoxic rats were pre-treated with carnosine, or L-arginine (200 mg/kg i.p.), or both. Carnosine and L-arginine were administered 24 hours and 1 hour before sodium nitrite injection.

Kim 2021 [175]	Ischemic strokes	Adult male SD rats	1000 mg/kg	i.v. to the tail	24 hours	Carnosine was administered 3 hours after ischemia induction.
Brown 2021 [176]	Parkinson's disease (motor dysfunction and impaired olfaction)	Thy1-aSyn (a model of PD) and wild-type mice	(0.0, 2.0, or 4.0 mg/day)	IN	8 weeks	
Banerjee 2021 [177]	Aging-induced proteinopathies	18- and 24-months male albino Wistar rats	2.0 µg/kg/day	i.t. injection	21 days	
Łochyński 2022 [178]	Neuromuscular diseases associated with aging	Male Wistar rats aged 15 months	1000mg/L (~ 46.0 mg/kg BW/day)	Drinking water	10 weeks or 34 weeks	Control plus two experimental groups in which 0.1% carnosine supplementation was performed for the last 10 weeks or for 34 weeks.
Arslan 2022 [179]	Exposure to a 900 Mhz electromagnetic field (EMF).	16-week-old female Wistar Albino rats weighing 200–250 g	Carnosine administered at low (10 mg/kg/day) and high (100 mg/kg/day) doses	i.p.	28 days	Control: Not exposed to any material, EMF, or carnosine injection. EMF group (EMGG): Exposed to EMF (900 MHz) 1 hour daily over 28 days. EMFG plus carnosine (CG): Exposed to EMF (900 MHz) 1 hour daily over 28 days, carnosine administered at low (10 mg/kg/day) and high (100 mg/kg/day) doses with i.p. injection

						provided 30 minutes before exposure.
Peng 2022 [180]	Diabetic encephalopathy (DE)	<i>db/db</i> mice	100 mg/kg	i.p./saline oral	8 weeks	
Tsuji 2022 [181]	Autism spectrum disorder (ASD)	C57BL6/N wild-type and CD157KO mice	0.09 g/100 mL	Drinking water	10 weeks	
Hegazy 2022 [182]	Glucose dysmetabolism Sporadic Alzheimer's disease (sAD)	Adult male Wistar rats (200–220 g)	100 mg/kg/day	Oral gavage	5 weeks	5 µL of either vehicle (0.9% saline for the control group) or STZ (3 mg/kg) dissolved in the same vehicle was slowly injected into the left ventricle.
Ndolo 2023 [183]	Diabetes Neurodegenerative diseases	SD rats	low (100 mg/kg), medium (300 mg/kg), and high (900 mg/kg)	Intra-gastric	12 weeks	High-fat diet (HFD) and one intraperitoneal injection of 30 mg/kg STZ, three intragastric carnosine treatment.
Hu 2023 [184]	Brain Stroke	mice	1000 mg/kg/day	Daily pre-treatment for 2 weeks and then 1 and 5 days after reperfusion	Transient MCAO mouse model for 60 minutes and continuously treated with saline or carnosine for additional 1 and 5 days after reperfusion.	
Rivi 2024 [185]	Inflammation	Pond snails <i>Lymnaea stagnalis</i> (six-month-old with shell lengths of 20–25 mm)	100 µM, 1 mM, or 10 mM	Carnosine dissolved in artificial pond water	1 hour	Exposure to 1 mM carnosine before training enhanced memory formation and neuroplasticity. Moreover, pre-exposure to 1 mM

						carnosine before LPS administration (approximately 8 mg/kg, injection) reversed the memory deficit brought about by inflammation.
Shen 2024 [186]	Postoperative cognitive dysfunction (POCD)	24-month-old male SD rats	250 mg/kg	i.p.	Half an hour before surgery	POCD model by exploratory laparotomy in 24-month-old male rats.
Chern 2025 [187]	Alzheimer's disease	Wild-type zebrafish (<i>D. rerio</i>)	10 mM	Tank with 10 mM CAR	30 days, 4 hours each day	4 experimental groups: 1. Fish exposed to 100 nM OKA, for 9 consecutive days to induce AD-like pathology. 2. Fish administered with 10 mM CAR for 30 consecutive days prior to a nine-day exposure to 100 nM OKA, 3. Fish administered with 10 mM CAR only for 39 days, 4. Healthy fish with no treatment.

During the last two decades, almost 200 *in vivo* studies have been published describing the therapeutic potential of carnosine. In neurological disease models, intranasal or intracerebral routes have been used as they provide direct access to the CNS. For example, intranasal carnosine (approximately 2–4 mg per day for 8 weeks) significantly improved motor function and reduced α -synuclein aggregation in a transgenic mouse model of Parkinson's disease (PD) (Thy1-aSyn), highlighting effective brain delivery and preventing the peripheral degradation due to circulating carnosinases [176]. By contrast, systemic carnosine injections in toxin-based Parkinsonian rodent models (e.g., 6-OHDA-lesioned rats or MPTP-treated mice) have been shown to attenuate dopaminergic neuron loss, elevate antioxidant enzyme levels, and dampen neuroinflammation in the striatum [148]. In Alzheimer's disease (AD) models, carnosine has been given orally, yielding reductions of amyloid- β (A β) accumulation and expression of neuroinflammatory markers [182], and a reduction of oxidative damage with improved cognition. Parenteral and intravenous carnosine treatments have demonstrated promising results in experimental stroke models when administered within the critical therapeutic window following vessel occlusion. It reduced infarct size and enhanced neurological recovery outcomes [169,175]. Beyond neurodegenerative models, carnosine has demonstrated therapeutic efficacy also in murine models of seizure and autism, further underscoring its broad preclinical therapeutic scope [163,180]. Carnosine's protective effects extend beyond the brain, as demonstrated by numerous researchers investigating its role in metabolic diseases and inflammatory conditions. In chronic metabolic and cardiovascular models, carnosine has been frequently delivered orally through drinking water or diet supplementation, with diabetic mice typically receiving high-dose treatments (often hundreds of mg per kg body weight per day). For instance, carnosine added to drinking water (~1 g/kg/day) over several months alleviated diabetic nephropathy, as evidenced by reduced albuminuria, retained podocyte integrity, and suppression of pro-fibrotic signaling in the kidneys [79]. Carnosine has also shown anti-inflammatory and antioxidant properties, exerting positive effects in various pathophysiological conditions, including autoimmune diseases [174]. In rodent models of acute lung injury (lipopolysaccharide-induced) and chemical nephrotoxicity, carnosine treatment demonstrates also immunomodulatory capacity through significant reductions in tissue tumor necrosis factor α (TNF- α), interleukin-16 (IL-6), and oxidative stress levels [71].

3. Non-neurological pathologies: Cancer, cardiovascular disease, diabetes, and metabolic syndrome

A growing body of literature evidence suggests that supplementation with carnosine, or its rate-limiting precursor β -alanine, can ameliorate different aspects of metabolic dysregulation that occur in diabetes and its related conditions as well as in other pathologies such as cardiovascular disease, cancer, lungs, or kidney dysfunction. L-carnosine acts by targeting key pathogenic pathways, including mitochondrial dysfunction, oxidative stress, inflammation, and impaired metabolic regulation [23].

Carnosine has been shown to enhance hepatic [Coenzyme Q (CoQ) gene expression and biosynthesis in a model of type 2 diabetes (*db/db* mice)]. Indeed, the administration of L-carnosine with CoQ improves mitochondrial function, reducing reactive oxygen species (ROS) production and mitigating cellular oxidative stress [89]. In the same model of type 2 diabetes (*db/db* mice), Peng *et al.* demonstrated that oral administration of carnosine (100 mg/kg for 8 weeks) also ameliorated cognitive impairment by reducing neuronal oxidative stress and inflammation, including inducible nitric oxide

(iNOS) expression and by modulating the Sirtuin 6/endoplasmic reticulum (ER) stress pathway in the hippocampus [180]. Consistent with the ability of carnosine to ameliorate cognitive impairment, it is worth mentioning the work on the activation of glutamatergic excitatory mechanisms and the related enhancement of the cognitive potential of the neural network promoted *in vitro* by carnosine [188].

Similarly, in streptozotocin (STZ)-diabetic rats, as shown by Ahshin-Majd *et al.* [65], chronic treatment with carnosine improved cognitive performance. In this work, the authors further explored the molecular mechanisms underlying carnosine's neuroprotective effects, showing a reduction of nuclear factor-kappaB (NF- κ B), TNF- α , and glial fibrillary acidic protein (GFAP) in the hippocampus. These effects were accompanied by activation of the antioxidant pathway, an improved cholinergic function, and an overall decrease of oxidative stress in diabetic rats. In diabetic Balb/cA mice, oral supplementation with histidine or carnosine (0.5 and 1 g/L added into drinking water) reduced inflammatory cytokines and inhibited glucose-induced low density lipoprotein oxidation and glycation, indicating a broad spectrum of protective effects [23].

Renal protection has also been reported. In a model of diabetic nephropathy, carnosine has been shown to attenuate renal tubular damage by inhibiting ferroptosis through its antioxidant and iron-chelating properties, with nuclear factor erythroid 2-related factor 2 (Nrf2) being central to this outcome [97]. Several other studies have described the role of CNDP1-carnosine axis in the progression of diabetic complications, especially diabetic nephropathy. Increased CNDP1 activity reduces both carnosine and anserine levels, worsening renal damage. On the contrary, carnosine supplementation restores their levels, improves metabolic balance, reduces oxidative stress, and preserves the podocyte number [42,48,58].

Chronic carnosine supplementation has shown to decrease oxidative stress and AGEs, maintain renal and hepatic function, and enhance glycemic control in type 2 diabetes models, such as high-fat diet and STZ-induced rats [79,81,82]. By partially scavenging reactive aldehydes, such as methylglyoxal, oral carnosine reduced glomerular damage and albuminuria in BTBR ob/ob mice, thereby reducing AGE-induced inflammation and apoptosis [91,97]. Notably, preliminary human trials have confirmed these advantages, demonstrating that 12-week oral supplementation lowers fasting glucose and glycated hemoglobin (HbA1c).

In addition to its positive effects on diabetes, carnosine exhibits hepatoprotective properties in various *in vivo* models of acute and chronic liver injury induced by agents such as thioacetamide (TAA), ethanol, acetaminophen, and cadmium [31,32,34,35]. In these studies, carnosine, either administered intraperitoneally (10–250 mg/kg/day) or via drinking water (0.5–2 g/L), showed strong protective effects. It counteracted oxidative stress, inflammation, reduced liver tissue damage, and supported the liver's natural antioxidant defenses, suggesting its potential in alleviating, or, in the best scenario, preventing chemically induced liver injury.

In lung injury and inflammation models, such as sepsis- and bleomycin-induced lung damage, carnosine treatment was effective in reducing oxidative stress, inflammatory cytokines [including TNF- α , IL-8, transforming growth factor-beta (TGF- β)], and tissue damage, while restoring antioxidant enzyme activity. These effects were associated with modulation of key signaling pathways, such as NF- κ B, and apoptosis regulation. Recent data also support its antifibrotic and antioxidant potential in cholestasis-induced pulmonary injury, reinforcing its relevance in lung-related inflammatory and fibrotic disorders [26,71].

In the context of cardiovascular diseases, ApoE $^{-/-}$ mice fed an atherogenic diet and treated with carnosine, revealed that the latter produced a reduction of atherosclerotic plaque formation along with

decreased lipid peroxidation and carbonyl stress, further proving the scavenging and the anti-inflammatory properties of this dipeptide [78,93]. Beyond metabolic and cardiovascular protection, carnosine has also shown promising antitumor properties. It inhibits tumor glycolysis, buffering extracellular acidosis, blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, and elevating oxidative stress over the threshold that malignant cells can tolerate. Although carnosine did not completely stop tumor development, mice treated with carnosine showed delayed tumor onset and slower progression compared to saline-treated controls; these effects were paralleled by a significant reduction in mitotic cells, suggesting that carnosine is effectively able to limit cancer cell proliferation *in vivo* [37].

Finally, in the ischemia-reperfusion models, carnosine preserved myocardial function and, at the same time, reduced infarct size by attenuating ROS levels and calcium overload [80,87]. While clinical data are limited, these preclinical findings point to carnosine's capacity to modulate key pathogenic mechanisms across diseases.

4. Carnosine and neurodegenerative diseases

4.1. Cellular and molecular mechanisms of carnosine in the CNS

Carnosine neuroprotective properties are attributed to its multimodal mechanism of action, including the well-known antioxidant activity [16,189]. *In vitro* studies have elucidated the cellular and molecular mechanisms through which carnosine exerts its effects within the CNS, particularly in the context of neurodegenerative diseases such as AD and PD [190,191]. In AD models, carnosine has demonstrated the ability to reduce the formation of A β 1-42 oligomers [192,193] and to mitigate A β -induced oxidative stress and neuroinflammation. In particular, in BV-2 microglial cells challenged with oligomeric A β 1-42, carnosine treatment resulted in decreased production of ROS and NO, along with a downregulation of iNOS and NADPH oxidase (Nox) enzymes [190]. Furthermore, carnosine modulated cytokine profiles by reducing pro-inflammatory IL-1 β levels while enhancing anti-inflammatory cytokines such as IL-10 and transforming growth factor-beta 1 (TGF- β 1). Notably, the neuroprotective effects of carnosine were blocked after inhibition of TGF- β 1 signaling, underscoring the pivotal role of this pathway in mediating its protective actions [190]. Consistently, researchers further characterized the immunomodulatory profile of carnosine in BV-2 microglial cells challenged with A β oligomers [194]. Carnosine treatment enhanced the gene expression of macrophage inflammatory protein 2-alpha (CXCL2) and IL-10, marking its anti-inflammatory effects. Moreover, it promoted a phagocytic phenotype by upregulating CD11b and CD68, and by restoring the fractaline receptor (CX3CR1) expression, a chemokine receptor involved in the fractalkine signaling implicated in microglial communication and A β clearance. Notably, carnosine also transcriptionally increased TGF- β 1 and its receptor expression, confirming the involvement of this pathway in promoting carnosine's neuroprotective response.

The ability of the dipeptide to serve as an A β antiaggregant has been also proved in novel formulations involving hyaluronan-carnosine conjugates [195]. Synthetic derivatives of hyaluronic acid functionalized with carnosine demonstrated a synergistic activity from the parent compounds able to inhibit the formation of amyloid-type aggregates of A β 1-42, showing an effect directly proportional to the amount of carnosine loaded in the formulation. Moreover, the novel formulation was also able to dissolve the amyloid fibrils and to reduce A β -induced toxicity *in vitro* in neuroblastoma cells.

Interestingly, authors speculated that one of the indirect methods used by hyaluronan-carnosine conjugates to facilitate the A β clearance was related to the ability to affect the early stage of A β enzymatic degradation mediated by the insulin-degrading enzyme (IDE). This effect seems to result from a conformational modulation of A β structure, rendering it more accessible to IDE-mediated proteolysis. In this context, a different research group confirmed the same concept, also highlighting the pivotal role of IDE in carnosine neuroprotection [195]. In rat mixed neuronal cultures, carnosine showed a protective behavior against A β 1-42 oligomers-induced toxicity; interestingly, the pharmacological inhibition of IDE in the presence of 6bK, a highly selective IDE inhibitor, abolished carnosine's neuroprotective actions, confirming a causal link between IDE function and carnosine efficacy. The authors also demonstrated that the IDE activating role of carnosine was due to the increase in the oligomerization and in the cooperativity of the enzyme, which facilitates the degradation of long substrates (including A β peptides). Confirming the suggestions from the above-mentioned work, the results showed that carnosine is able to improve the activity of IDE by enhancing the affinity for long substrates and, in turn, the overall catalytic activity, avoiding a direct binding with the enzyme.

Recent evidence has further highlighted the antioxidant role of carnosine in the context of AD-related neuroinflammation, particularly considering the cross-talk between microglia and astrocytes, two cell types crucial for supporting neuronal functions [197]. In the study conducted on an AD model of primary mixed glial cultures, composed of both microglia and astrocytes from rat, the exposure to A β oligomers induced a significant increase in intracellular ROS and NO levels, while the co-treatment with carnosine markedly reduced these oxidative stress markers, preventing cytotoxic effects. In addition, single-cell analysis revealed that carnosine not only suppressed the mean levels of ROS, but also minimized cell-to-cell variability in oxidative responses, suggesting a stabilizing effect on glial reactivity [197].

In a PD context, specifically performed on GT1-7 hypothalamic neuronal cells treated with 6-hydroxydopamine (6-OHDA), a neurotoxin that induces PD-like pathology, carnosine administration attenuated cell death and suppressed the expression of integrated stress response (ISR)-related genes, including the CCAAT-enhancer-binding protein homologous protein (CHOP), the growth-arrest and DNA-damage-inducible gene 34 (GADD34), and the activating transcription factor 4 (ATF4). Additionally, carnosine inhibited ROS production and the activation of the c-Jun N-terminal kinase (JNK) pathway, suggesting a mechanism involving the suppression of oxidative stress-mediated apoptotic signaling [191]. In *in vivo* and *in vitro* rat models of PD, performed by salsolinol-induced toxicity, Zhao *et al.* demonstrated that carnosine administration restored antioxidant enzyme levels, including superoxide dismutase (SOD), catalase, and glutathione, reduced lipid peroxidation (malondialdehyde (MDA)), and decreased ROS in brain tissue and rat brain endothelial cells [155]. Histopathological analysis further confirmed that carnosine attenuated neuronal apoptosis, preserving cellular architecture. The proposed results validate the antioxidant and cytoprotective effects of carnosine in a toxin-based PD model, remarking its potential to mitigate oxidative damage to the neurovascular unit. The dysregulation of metal ions observed in PD models and the vascular type of dementia, particularly zinc, contributes significantly to oxidative stress and dopaminergic neurodegeneration. Carnosine, due to its metal-chelating capacity and antioxidant properties, has been proposed as a protective agent against zinc-induced neurotoxicity [198]. Notably, carnosine was shown to inhibit the Zn²⁺-induced expression of ER-stress-related genes, including GADD34 and CHOP [199], attenuate zinc-induced mitochondrial dysfunction, reduce intracellular ROS accumulation, and preserve dopaminergic neuron viability [200]. These findings support the

hypothesis that carnosine may counteract zinc-mediated oxidative pathways implicated in the pathogenesis of PD and vascular dementia.

The neuroprotective properties of carnosine in an *in vitro* model of hemorrhagic stroke have been demonstrated [201]. The authors, by employing this model, were able to demonstrate a block of AMPA, NMDA GABA receptors' activity as a consequence of autoblood (blood clot), while an opposite effect was observed with carnosine, that when used as a pre-treatment was able to restore the activity of these key receptors. Carnosine was also able to reduce tissue swelling in olfactory cortex slices of hypertensive rats under autoblood. The protective activity of carnosine on the brain microvascular endothelial cell environment was also proved in a mouse *in vitro* model exposed to rotenone [202]. Interestingly, authors found that carnosine reduced the number of apoptotic cells and restored the decrease in mitochondrial membrane potential due to rotenone treatment, while these effects were reversed by the treatment with histamine H1 receptor antagonists (pyrilamine and diphenhydramine) and H2 receptor antagonists (cimetidine and zolatidine). These findings indicate that carnosine's ability to protect brain microvascular endothelial cells under oxidative status may be mediated by H1 and H2 receptors. The role of carnosine in the link between blood flow and ischemic stroke has been also proved in endothelial F-2 cells, in which the dipeptide showed to strongly modulate NO signaling [203]. In this *in vitro* study, carnosine dose-dependently enhanced NO production, while in contrast, its components β -alanine and L-histidine and analogue anserine (*N*-methyl-carnosine) failed to increase NO production. Notably, carnosine increased intracellular Ca^{2+} levels, essential for NO production, even in the absence of extracellular Ca^{2+} . Although carnosine did not induce phosphorylation of endothelial NOS (eNOS) at Ser1177, the findings suggest that the dipeptide is able to activate eNOS via a Ca^{2+} -dependent but phosphorylation-independent mechanism, involving the release from intracellular Ca^{2+} storage.

The specific activity of carnosine on astrocytes has been also widely assessed. *In vitro* studies have revealed that carnosine is able to protect astrocytes against NO-induced mitochondrial dysfunction by reducing the expression of oxidative stress-responsive genes, including poly (ADP-ribose) polymerase-1 (PARP-1) and -2 (PARP-2), thus preserving cellular integrity under stress conditions [204]. Furthermore, in primary astrocytes exposed to oxygen-glucose deprivation/recovery (a model mimicking ischemia), millimolar concentrations of carnosine reversed the expression of matrix metalloproteinase-9 (MMP-9), promoting axonal regrowth in astrocyte-neuron co-cultures [205]. These findings underline the ability of carnosine to enhance the astrocytic functions, promoting neuro-regeneration after injury. An additional *in vitro* study has also demonstrated that carnosine is available to be phagocytized by RAW 264.7 macrophagic cells, an *in vitro* model frequently used to mimic the microglia behavior, particularly under oxidative stress conditions, where its uptake can increase up to threefold [206]. This selective accumulation suggests a role for carnosine in modulating microglial oxidative responses. Indeed, carnosine treatment was reported to reduce the production of ROS in nanoparticle-exposed microglia, implicating its potential ability in counteracting environmental neuroinflammation [207]. These *in vitro* results underscore carnosine's multimodal mechanism of action in brain cells, including astrocytes and microglia, highlighting its antioxidative and anti-inflammatory capabilities that may be crucial in the context of neurodegeneration and CNS injury. Finally, carnosine has also been shown to stimulate the secretion of neurotrophins such as Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in human glioblastoma-derived U-87 MG cells, but not in neuronal SH-SY5Y cells, suggesting a cell type-specific mechanism of action [208].

Figure 2 summarizes the *in vitro* models employed to investigate the therapeutic potential of carnosine at the CNS level.




Figure 2. CNS *in vitro* models and molecular mechanisms modulated by carnosine. *In vitro* carnosine treatment has shown cell line-specific effects. In GT1–7 hypothalamic neurons, it enhances metal chelation and supports the integrated stress response. In U-87 MG glioblastoma cells, it increases the production of neurotrophic factors. In RAW 264.7 macrophages, carnosine uptake is tripled under stress conditions. In rat mixed cultures, it promotes insulin-degrading enzyme (IDE) oligomerization. In neuroblastoma cells, it facilitates the dissolution of A β oligomers. In endothelial F-2 cells, it reduces apoptosis and enhances nitric oxide (NO) production. In BV-2 microglial cells, carnosine displays anti-inflammatory activity, reduces reactive oxygen species (ROS) production, and increases phagocytosis.

4.2. Pathologies characterized by carnosine deficiency and/or impairment of carnosine-related enzyme activities

As described and clearly reported in Table 1, the therapeutic potential of carnosine has been investigated in a plethora of pathological conditions, underlining the strong consideration of this dipeptide as a possible treatment. It is also worth considering the “physiological importance” of carnosine; in fact, a well-balanced metabolism of carnosine and the maintenance of its homeostatic levels in biological fluids (e.g., blood and urine) and tissues have been reported.

The most representative deficiency in carnosine metabolism is represented by a decreased or absent activity of CNDP1 enzyme, leading to carnosinemia. The latter is a rare metabolic disorder characterized by increased levels of carnosine in urine (carnosinuria), low levels or absence of

carnosinase in the blood, and, most importantly, severe neurological symptoms and developmental delays in humans [4]. From a genetic point of view, carnosinemia has an autosomal recessive pattern of inheritance, with the defective gene that has been identified to be on chromosome 18 (18q21.3). Low activity of CNDP1 has also been coupled to homocarnosinemia with increased liquor and plasma levels of the carnosine's homolog homocarnosine (a dipeptide composed by GABA and histidine) as well as urinary excretion of homocarnosine; these metabolic alterations were accompanied by moderate neuropathological symptoms [209].

With regard to abnormal carnosine levels in biological fluids, carnosinuria has been reported in children suffering from cerebro-macular degeneration, as described by Bessman and Baldwin [210] and Levenson *et al.* [211] more than 50 years ago. Fonteh *et al.* investigated free amino acid and dipeptide changes in the body fluids from AD subjects, demonstrating that carnosine levels were significantly lower in plasma of probable AD subjects compared to controls (an opposite trend was observed for L-DOPA) and linking the abnormal levels of the dipeptide to cognitive impairment measured by mini-mental state examination (MMSE) and Alzheimer's Disease Assessment Scale-cognitive subscale (ADS-cog) [212]. Of note, significantly reduced levels of carnosine compared to healthy subjects have also been coupled to mitochondrial energetic impairments in age-related macular degeneration (AMD) patients [213]. Going back to AD, in a study carried out by Balion *et al.*, carnosinase activity was measured in patients with AD and mixed dementia, showing altered activities of the CNDP1 enzyme in patients with dementia [214]. Reduced serum carnosinase activity has also been observed in patients with other CNS disorders such as PD and multiple sclerosis [215].

4.3. AD, PD, and stroke

Carnosine supplementation has been reported to have beneficial effects on different experimental models of aging-related and neurodegenerative pathologies, including multiple sclerosis, depression, and post-operative cognitive dysfunction. However, in the following review sections, our interest was to examine the scientific literature on acute cerebral ischemia, AD, and PD models. Figure 3 reports the molecular pathways modulated by carnosine related to its neuroprotective potential in the context of these pathological conditions.




Figure 3. Neuroprotective potential of carnosine in cerebral ischemia, AD, and PD *in vivo* models. Rodent models have been used to demonstrate the neuroprotective potential of carnosine in cerebral ischemia and Parkinson's disease (PD). In ischemic stroke, carnosine reduces infarct volume and brain edema, chelates zinc ions, and promotes vasodilation through histamine production derived from histidine. In PD models, it decreases α -synuclein-positive cell bodies and improves motor deficits. Carnosine also reduces brain lipid peroxidation and enhances dopamine metabolism, a mechanism also observed in Alzheimer's disease (AD), where it further decreases A β aggregation and τ hyperphosphorylation, and improves cognitive function. In AD research, carnosine's effects have been studied not only in rodents but also in nematodes (*C. elegans*) and fish (zebrafish). Across all models, carnosine has consistently shown anti-excitotoxic, antioxidant, and mitochondrial-protective properties.

4.3.1. Ischemic stroke

Stroke remains one of the leading causes of death globally, with ischemic stroke, caused by obstruction of blood flow, accounting for approximately 87% of all cases [216]. In acute ischemic stroke, the rapid loss of blood flow to an area of the brain results in a consistent loss of neurologic functions. Such blood decrease rapidly causes neuronal necrosis, followed by inflammatory cascade and significant oxidative stress stimulation during reperfusion. Therefore, treatments that mitigate cell damage (oxidative stress and neuroinflammation) until blood supply is restored are urgently needed, and our aim is to provide greater clarity and organization to the literature on this topic.

Carnosine has shown important neuroprotective effects in animal models of ischemia. It has been shown to significantly reduce infarct volume and brain edema following ischemic stroke. Numerous published studies have demonstrated that carnosine shows strong efficacy in ischemic stroke models [217]. In these studies, infarct volume was used as the primary outcome measure, while the neurobehavioral

score was the secondary outcome. Eight animal stroke studies (454 subjects) showed that carnosine effectively reduces infarct volume, with the highest efficacy at a dose of 1000 mg/kg. The treatment was most effective when given within 6 hours of ischemia onset, but showed some benefit beyond that window. This timing is clinically relevant, as the median hospital arrival time for stroke patients is 4.3 hours [218]. This is in line with findings by Park *et al.* [139], where early intraperitoneal administration of carnosine (up to 500 mg/kg) significantly reduced infarct volume and increased antioxidant expression, emphasizing the importance of early intervention.

In rats, carnosine demonstrated strong protective effects in permanent and transient ischemic stroke models, with therapeutic frames up to 9 and 6 hours, respectively. Together with improved histological and functional outcomes, carnosine exerted anti-excitotoxic, antioxidant, and mitochondrial protective actions [126,169]. Rats treated with carnosine, prior to inducing a transient ischemia, exhibited smaller areas of neuronal damage and a better cell survival in vulnerable regions compared to untreated controls. This effect is partly due to the reduction in oxidative and nitrosative stress during reperfusion, as well as the inhibition of astrocyte and microglia activation and the decrease in excitotoxic mediators (e.g., extracellular glutamate, which is taken up more by astrocytes because of carnosine) [123,219]. Additional mechanistic insight comes from pMCAO models where carnosine has been shown to activate STAT3/Pim-1 pathway, upregulated Bcl-2, and reduced caspase-3, indicating its involvement in the regulation of anti-apoptotic signaling [136]. Moreover, carnosine possesses vasodilatory properties through its hydrolysis into β -alanine and L-histidine and local histamine formation, which may help improve perfusion in the penumbral regions surrounding the infarct. Noteworthy, the therapeutic window and the administration route are critical for the efficacy of carnosine. Indeed, carnosine administration (i.p.) immediately after the arterial occlusion procedure appears to be effective, while a delay in the treatment diminishes its efficacy [137,138]. This suggests that carnosine, in a clinical setting, might be considered an acute neuroprotective treatment to be administered early during stroke/reperfusion and in combination with other drugs or therapies.

Treatment with carnosine on ischemic stroke mice, whether given as a preventive measure or within the first hour post-stroke, reduced the extent of brain lesions and improved neurological recovery. Indeed, Kim *et al.* demonstrated a neuroprotective effect for carnosine by inhibiting MMP-2 and MMP-9 activity through zinc chelation [175]. Given the crucial role of blood-brain barrier (BBB) preservation in limiting secondary injury, this aligns with recent anti-stroke strategies that increasingly focus on BBB-permeable drugs with multiple sites of action. In parallel, β -alanine, a natural precursor of carnosine, has also shown neuroprotective properties. Kopach *et al.* demonstrated that β -alanine protects brain cells under stroke-like conditions via multiple, distinct pharmacological mechanisms [220]. Given its ability to cross the BBB and its dietary availability, β -alanine also holds promise as an adjunctive therapy for stroke recovery.

4.3.2. Alzheimer's disease

Numerous preclinical studies have investigated the effect of carnosine on *in vitro* or *in vivo* models of AD to determine its effect on pathological hallmarks such as amyloid aggregation, oxidative stress, and neuroinflammation.

As mentioned, one part of the scientific works had investigated the effect of carnosine by using *in vitro* models, showing how it protects against A β -induced toxicity by preventing amyloid aggregation and by diminishing oxidative stress and inflammation [190,192,193]. Carnosine acts by

lowering intracellular NO and iNOS expression, modulating cytokine release, and enhancing TGF- β production. It also promotes neurotrophins expression (NGF, BDNF) [208] and simultaneously prevents their degradation by inhibiting metalloproteases.

Moving to *in vivo* studies, and in particular those involving *C. elegans*, carnosine reduced A β aggregation by activating the cytosolic unfolded protein response via Heat shock factor protein 1 (HSF-1) and downstream chaperones, improving proteostasis and attenuating AD-like phenotypes [221]. Many AD patients exhibit dysregulation of metal ions, such as copper and zinc, leading to accumulation of A β aggregation. In a *C. elegans* model of AD, copper chelation with β -alanine has been shown to reduce ROS production and to modulate the expression of oxidative stress genes, therefore increasing lifespan [222]. In a zebrafish AD model induced by exposure to okadaic acid, carnosine administration prevented cognitive and motor deficits, reduced tau hyperphosphorylation and A β accumulation, and preserved dopaminergic function [187]. These results highlight its multimodal neuroprotective effects, particularly in early-stage AD-like pathology. In rodent models, carnosine supplementation led to decreased A β accumulation, reduced lipid peroxidation, and improved mitochondrial function, resulting in enhanced cognitive performance. These effects were linked to carnosine's antioxidant and Zn $^{2+}$ -chelating properties [130]. In a rat STZ-induced model of cognitive impairment (i.c.v. injection), daily oral carnosine (100 mg/kg) supplementation, along with swimming paradigm, contributes by restoring hippocampal FNDC5/irisin expression, improving insulin signaling, and reducing A β and phosphorylated tau levels. These effects were paralleled by enhanced BDNF expression and improved cognitive performance. Overall, carnosine showed neuroprotective effects comparable to exercise, supporting its therapeutic potential in AD-like conditions [182]. The 3xTg-AD mouse is a widely used transgenic model of AD that carries mutations in APP (Swedish), MAPT (P301L), and PSEN1 (M146V), and is known to develop A β plaques and neurofibrillary tangles [223]. In 3xTg-AD mice, chronic supplementation with carnosine (10 mM in drinking water) led to a significant reduction in intraneuronal A β accumulation within the hippocampus and improved mitochondrial function, with a trend toward the amelioration of cognitive deficits [130].

In APP/PS1 mice, treatment with anserine, the N-methylated form of carnosine, improved spatial memory and significantly reduced neuroinflammation and pericyte degeneration, two key elements at the basis of neurovascular dysfunction. In 3xTg-AD mice fed a high-fat diet (HFD), daily treatment with carnosine (5 mg/day for 6 weeks) effectively prevented cognitive decline, with treated animals displaying memory performance comparable to controls. Although no significant differences in senile plaque load were detected across groups, carnosine markedly reversed HFD-induced microglial activation in the hippocampus and reduced receptor for advanced glycation end-product (RAGE) overexpression in cerebral blood vessels. These findings highlight carnosine's protective role against diet-induced neuroinflammation and cerebrovascular dysfunction. In parallel, anserine boosted pericyte coverage, reduced astrogliosis, and lowered IL-1 β levels, suggesting a protective effect on the neurovascular unit [135]. These findings highlight the effect of anserine in counteracting cognitive decline through vascular and anti-inflammatory actions. Furthermore, in a type 2 diabetes model, carnosine improved cognitive deficits without affecting blood glucose levels or body weight. It enhanced antioxidant response, reduced lipid peroxidation, and modulated autophagy via activation of the Akt/mTOR pathway. These effects were accompanied by reduced neuronal damage and a better memory performance. Thus, carnosine appears to be effective by reducing diabetes-related cognitive decline through mechanisms independent of glycemic control [183].

4.3.3. Parkinson's disease

Several researchers have assessed the potential of carnosine to treat PD, where oxidative stress and mitochondrial dysfunction play key roles in pathogenesis. Here, we present the results obtained in studies where carnosine's beneficial effects have been demonstrated in neurotoxin-induced and genetic knockout animal models of PD.

In an MPTP-induced mouse model of PD, pre-treatment with carnosine (administered via drinking water [0.5–2 g/L for 4 weeks]) significantly attenuated oxidative stress and inflammation in the striatum, thus protecting against neuronal death. This was accompanied by an improvement in motor deficits induced by MPTP, along with a reduction in brain lipid peroxidation [127]. Similarly, in a rotenone-induced rat model of PD, a nanomicellar complex of carnosine and lipoic acid administered intraperitoneally (25–50 mg/kg) reduced oxidative stress, improved antioxidant capacity, increased neuron density in the *substantia nigra*, and partially restored dopamine levels and motor activity, supporting the therapeutic potential of carnosine formulations with enhanced bioavailability [224]. In addition, carnosine has been shown to exert neuroprotective effects by enhancing the activity of antioxidant enzymes such as glutathione peroxidase (GPX) and superoxide dismutase (SOD) while reducing pro-inflammatory markers, including IL-6, TNF- α , and iNOS. Its combined antioxidant and anti-inflammatory effects also improved dopamine metabolism, helping to protect dopaminergic neurons from degeneration and cell death.

According to Zhao and collaborators [155], carnosine treatment in salsolinol-induced rat models demonstrated significant neuroprotective effects by not only normalizing antioxidant enzyme levels and reducing lipid peroxidation markers, but also by substantially decreasing mitochondria-derived ROS production in endothelial cells while preserving cellular architecture integrity in brain tissue. These findings suggest that carnosine's protective mechanism extends beyond conventional antioxidant activity to encompass mitochondrial function preservation, an effect consistent with broader preclinical research demonstrating carnosine's multimodal actions, including antioxidant, anti-inflammatory, and anti-aggregate properties across neurodegenerative disease models, including PD, thereby supporting its potential as a disease-modifying agent [189].

Beyond neurotoxicity-induced models, carnosine administration has also been tested on transgenic models of PD. In a study conducted on mice overexpressing human α -synuclein (Thy1- α Syn model [167]), two carnosine administration routes were compared: the intranasal route versus the oral route. Transcriptomic analysis revealed that α -synuclein overexpression was primarily associated with impaired ribosomal biogenesis and compromised mitochondrial function. Notably, after two months of treatment, mice receiving carnosine treatment intranasally exhibited significantly amelioration in gene expression profiles and mitochondrial function compared to oral treatment, suggesting that this therapeutic approach effectively targets key molecular pathways disrupted in PD pathogenesis through enhanced brain bioavailability.

A subsequent study demonstrated that intranasal carnosine administration (2.0 or 4.0 mg/day for 8 weeks) produced dose-dependent improvements in motor function in Thy1- α Syn mice [176]. Complementary results on the same Thy1- α Syn model have been obtained in Bermúdez *et al.* with intranasal carnosine treatment (2 mg/day for 2 months) [167,168]. Moreover, researchers have showed preserved gait performance and reduced α -synuclein immunoreactivity in the olfactory epithelium, further supporting the enhanced efficacy of nasal administration and its ability to limit pathological protein deposition [168]. Furthermore, carnosine treatment significantly reduced α -synuclein-positive

cell bodies in the *substantia nigra pars compacta* to levels comparable with vehicle-treated wild-type mice, indicating that carnosine reduces pathological α -synuclein accumulation in motor-related brain regions, offering mechanistic support for its therapeutic potential in PD progression. Overall, in PD, carnosine appears to maintain redox homeostasis in dopaminergic cells and prevent the formation of toxic α -synuclein oligomers. In a 6-OHDA-induced PD model, pre-treatment with carnosine (250 mg/kg i.p.) significantly attenuated motor symptoms, apoptosis, and oxidative damage, confirming its early neuroprotective action in dopaminergic degeneration [148].

Beyond AD and PD, carnosine has been evaluated in other neurological contexts, showing beneficial effects in models of depression (enhancing hippocampal neurogenesis in chronically stressed rats) [119], seizure [117,122,164], autism [181], and in cognitive dysfunction (where it appears to mitigate glial inflammation [186]). This broad spectrum of actions put carnosine as a homeostatic modulator of the neuronal microenvironment that probably acts by rocketing existing neuroprotective pathways than the activation of new mechanisms.

5. *In vivo* research on carnosine: What was achieved and what is missing

Despite the very promising findings reported above, it is very challenging to compare results across so many studies due to the great heterogeneity in terms of experimental approaches used, including different species (from worms to different rodent strains), a wide range of dosages along with very different treatment durations, and multiple delivery routes. Additionally, one of the most urgent needs, enabling us to better comprehend the enormous therapeutic potential of carnosine, is represented by carrying out pharmacokinetics studies, connecting the dose administered to the one arriving at the site of action and able to provide the benefit observed. In this regard, a very recent and informative paper was published by Ali *et al.* [225]. The authors employed proton magnetic resonance imaging (MRI) spectroscopy to evaluate the effect of oral dosing on brain carnosine concentrations in humans while investigating safety and tolerability, providing information on dosing interventions in future clinical trials. Similar studies should be re-proposed *in vivo* by employing the same models, then enabling us to better understand the efficacy of this pleotropic endogenous molecule. Moving in this direction, in collaboration with Prof. Lunte's group at the University of Kansas, we carried out pharmacokinetic studies on rats in which carnosine bioavailability at the brain level (e.g., ventral striatum), following the i.p. administration of 250 mg/kg of carnosine, was measured through microdialysis, a preferred sampling method for continuous monitoring of biomolecules in the extracellular space of various organs such as the brain [226]. Our preliminary results suggest that a single i.p. administration ensures a quick increase of carnosine at the brain level (i.e., 10 minutes after the injection), increasing its basal concentration up to 4 times compared to the basal level, with the increase being stable for about 40 minutes. Further studies are ongoing.

The inhibition of carnosinase activity has emerged as a promising strategy to prolong carnosine's half-life and increase its therapeutic effect. Bestatin is a dipeptide containing an unusual β -amino acid that makes it resistant to hydrolysis by carnosinase and rapidly forms a stable enzyme–inhibitor complex. This interaction effectively blocks carnosinase activity, with a higher affinity for CNDP2 than for CNDP1 [227], thereby preserving circulating histidine-containing dipeptides and improving their bioavailability *in vivo* [228]. Similarly, carnostatin (SAN9812) has been identified as the first selective and effective inhibitor of CNDP1 [229]. It acts as a competitive inhibitor, preventing the rapid hydrolysis of carnosine, and thereby enhancing its stability and availability in the body, which in turn

increases its antioxidant and anti-glycating effects [230]. Its action has been also validated in transgenic mice expressing the human CNDP1 gene, where the co-administration with carnosine resulted in a sustained increase of circulating carnosine without adverse effects on the central nervous system. Beyond these, additional approaches have been proposed, such as the carnosinase-resistant D-carnosine pro-drug, D-carnosine-octylester [231], that proved to be successful in attenuating atherosclerosis and renal disease induced by a western diet or streptozotocin-induced diabetes in the ApoE-null mice [47,63]. Another approach that has been explored is the use of carnosinol, a (2S)-2-(3-amino propanoyl amino)-3-(1H-imidazol-5-yl)propanol (FL-926-16), a new carnosinase-resistant L-carnosine derivative that has shown to counteract diabetic nephropathy [76]. Together, this evidence strengthens the concept that combining carnosine supplementation with pharmacological inhibition of its degrading enzymes could represent a powerful and effective strategy to fully extend the complete therapeutic potential of this dipeptide.

Last but not least, it is important to underline the use of carnosine in combination with anserine, a natural derivative of carnosine usually adopted because it is not cleaved by human carnosinases. This “protocol”, which is very often considered and used at the clinical level [232–238], is almost completely missing in preclinical studies, suggesting that, like the studies mentioned, considering the supplementation of carnosine in combination with anserine may lead to better results, providing a better alignment between preclinical and clinical studies.

6. Future perspectives and concluding remarks

Since its discovery, thousands of research studies have been carried out to investigate the role, function, and biological activities of carnosine under physiological and pathological conditions, illustrating the substantial attention that this molecule has garnered within the scientific community. With regard to *in vivo* studies, both the importance of maintaining carnosine physiological levels as well as its multimodal mechanism of action in numerous systemic and neurodegenerative disorders have been well demonstrated. Despite the enormous therapeutic potential, our focus of this review was to critically highlight the strengths and weaknesses of carnosine, as in the case of the significant heterogeneity regarding administration route, dosage, treatment, and animal model selected. More translational studies are needed to better understand the literature, which will enable us to accurately plan future and well-defined clinical studies.

Use of AI tools declaration

The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

Acknowledgments

This research received no external funding.

Conflict of interest

The authors declare no conflict of interest.

Authors' contributions

Project administration and conceptualization of the manuscript: G. Caruso; literature search: S.A.B., G. Carota, K.P., L.D., A.P., V.C., A.G., R.M., and G. Caruso; writing—original draft: S.A.B., G. Carota, and G. Caruso; preparation of the figures: G. Caruso and L.D.; writing—review & editing: S.A.B., G. Carota, K.P., L.D., A.P., V.C., A.G., R.M., Giu. L., B.T., V.D., E.M., F.B., A.M.A, Gia. L., S.P.B., G. Caruso; All Authors made a substantial, direct, and intellectual contribution to the review, and reviewed and approved its final version.'

References

1. Gulewitsch W, Amiradžibi S (1900) Ueber das Carnosin, eine neue organische Base des Fleischextractes. *Ber Dtsch Chem Ges* 33: 1902–1903. <https://doi.org/10.1002/cber.19000330275>
2. Jędrzejko M, Kała K, Muszyńska B (2025) Anserine, Balenine, and Ergothioneine: Impact of Histidine-Containing Compounds on Exercise Performance-A Narrative Review. *Nutrients* 17: 828. <https://doi.org/10.3390/nu17050828>
3. Kawahara M, Tanaka KI, Kato-Negishi M (2018) Zinc, Carnosine, and Neurodegenerative Diseases. *Nutrients* 10: 147. <https://doi.org/10.3390/nu10020147>
4. Caruso G, Caraci F, Jolivet RB (2019) Pivotal role of carnosine in the modulation of brain cells activity: Multimodal mechanism of action and therapeutic potential in neurodegenerative disorders. *Prog Neurobiol* 175: 35–53. <https://doi.org/10.1016/j.pneurobio.2018.12.004>
5. Boldyrev AA, Aldini G, Derave W (2013) Physiology and pathophysiology of carnosine. *Physiol Rev* 93: 1803–1845. <https://doi.org/10.1152/physrev.00039.2012>
6. Teufel M, Saudek V, Ledig JP, et al. (2003) Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. *J Biol Chem* 278: 6521–6531. <https://doi.org/10.1074/jbc.M209764200>
7. Lenney JF, George RP, Weiss AM, et al. (1982) Human serum carnosinase: characterization, distinction from cellular carnosinase, and activation by cadmium. *Clin Chim Acta* 123: 221–231. [https://doi.org/10.1016/0009-8981\(82\)90166-8](https://doi.org/10.1016/0009-8981(82)90166-8)
8. Lenney JF (1990) Human cytosolic carnosinase: evidence of identity with prolinase, a non-specific dipeptidase. *Biol Chem Hoppe Seyler* 371: 167–171. <https://doi.org/10.1515/bchm3.1990.371.1.167>
9. Mokrushin AJAnRanSb (2024) Dipeptide L-carnosine (β -alanyl-L-histidine)—nervous tissue cryoprotector non-hibernate animals. *Izvestiâ Akademii nauk. Rossijskaâ akademiiâ nauk. Seriâ biologîcheskaâ* 2024: 346–357. <https://doi.org/10.31857/S1026347024030064>
10. Caruso G, Fresta CG, Martinez-Becerra F, et al. (2017) Carnosine modulates nitric oxide in stimulated murine RAW 264.7 macrophages. *Mol Cell Biochem* 431: 197–210. <https://doi.org/10.1007/s11010-017-2991-3>
11. Fresta CG, Fidilio A, Lazzarino G, et al. (2020) Modulation of Pro-Oxidant and Pro-Inflammatory Activities of M1 Macrophages by the Natural Dipeptide Carnosine. *Int J Mol Sci* 21: 776. <https://doi.org/10.3390/ijms21030776>
12. Spaas J, Franssen WMA, Keytsman C, et al. (2021) Carnosine quenches the reactive carbonyl acrolein in the central nervous system and attenuates autoimmune neuroinflammation. *J Neuroinflammation* 18: 255. <https://doi.org/10.1186/s12974-021-02306-9>

13. Aloisi A, Barca A, Romano A, et al. (2013) Anti-aggregating effect of the naturally occurring dipeptide carnosine on $\alpha\beta 1-42$ fibril formation. *PLoS One* 8: e68159. <https://doi.org/10.1371/journal.pone.0068159>
14. Hasanein P, Felegari Z (2017) Chelating effects of carnosine in ameliorating nickel-induced nephrotoxicity in rats. *Can J Physiol Pharmacol* 95: 1426–1432. <https://doi.org/10.1139/cjpp-2016-0647>
15. Baba SP, Hoetker JD, Merchant M, et al. (2013) Role of aldose reductase in the metabolism and detoxification of carnosine-acrolein conjugates. *J Biol Chem* 288: 28163–28179. <https://doi.org/10.1074/jbc.M113.504753>
16. Berezhnoy DS, Stvolinsky SL, Lopachev AV, et al. (2019) Carnosine as an effective neuroprotector in brain pathology and potential neuromodulator in normal conditions. *Amino Acids* 51: 139–150. <https://doi.org/10.1007/s00726-018-2667-7>
17. Caruso G (2022) Unveiling the Hidden Therapeutic Potential of Carnosine, a Molecule with a Multimodal Mechanism of Action: A Position Paper. *Molecules* 27: 3303. <https://doi.org/10.3390/molecules27103303>
18. Bonaccorso A, Privitera A, Grasso M, et al. (2023) The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development. *Pharmaceuticals (Basel)* 16: 778. <https://doi.org/10.3390/ph16060778>
19. Décombaz J, Beaumont M, Vuichoud J, et al. (2012) Effect of slow-release β -alanine tablets on absorption kinetics and paresthesia. *Amino acids* 43: 67–76. <https://doi.org/10.1007/s00726-011-1169-7>
20. Salatto RW, McGinnis GR, Davis DW, et al. (2021) Effects of Acute Beta-Alanine Ingestion and Immersion-Plus-Exercise on Connectedness to Nature and Perceived Pain. *Int J Environ Res Public Health* 18: 8134. <https://doi.org/10.3390/ijerph18158134>
21. Aldini G, de Courten B, Regazzoni L, et al. (2021) Understanding the antioxidant and carbonyl sequestering activity of carnosine: direct and indirect mechanisms. *Free Radic Res* 55: 321–330. <https://doi.org/10.1080/10715762.2020.1856830>
22. Chmielewska K, Dzierzbicka K, Inkielewicz-Stępnia I, et al. (2020) Therapeutic Potential of Carnosine and Its Derivatives in the Treatment of Human Diseases. *Chem Res Toxicol* 33: 1561–1578. <https://doi.org/10.1021/acs.chemrestox.0c00010>
23. Lee YT, Hsu CC, Lin MH, et al. (2005) Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. *Eur J Pharmacol* 513: 145–150. <https://doi.org/10.1016/j.ejphar.2005.02.010>
24. Tanida M, Niijima A, Fukuda Y, et al. (2005) Dose-dependent effects of L-carnosine on the renal sympathetic nerve and blood pressure in urethane-anesthetized rats. *Am J Physiol Regul Integr Comp Physiol* 288: R447–455. <https://doi.org/10.1152/ajpregu.00275.2004>
25. Kurata H, Fujii T, Tsutsui H, et al. (2006) Renoprotective effects of L-carnosine on ischemia/reperfusion-induced renal injury in rats. *J Pharmacol Exp Ther* 319: 640–647. <https://doi.org/10.1124/jpet.106.110122>
26. Cuzzocrea S, Genovese T, Failla M, et al. (2007) Protective effect of orally administered carnosine on bleomycin-induced lung injury. *Am J Physiol Lung Cell Mol Physiol* 292: L1095–1104. <https://doi.org/10.1152/ajplung.00283.2006>
27. Mahmoud AH (2006) Comparative study between carnosine and fluvastatin in hypercholesterolemic rabbits. *J Appl Sci* 6: 1725–1730. <https://doi.org/10.3923/jas.2006.1725.1730>

28. Sauerhöfer S, Yuan G, Braun GS, et al. (2007) L-carnosine, a substrate of carnosinase-1, influences glucose metabolism. *Diabetes* 56: 2425–2432. <https://doi.org/10.2337/db07-0177>
29. Fouad AA, El-Rehany MA, Maghraby HK (2007) The hepatoprotective effect of carnosine against ischemia/reperfusion liver injury in rats. *Eur J Pharmacol* 572: 61–68. <https://doi.org/10.1016/j.ejphar.2007.06.010>
30. Kamei J, Ohsawa M, Miyata S, et al. (2008) Preventive effect of L-carnosine on changes in the thermal nociceptive threshold in streptozotocin-induced diabetic mice. *Eur J Pharmacol* 600: 83–86. <https://doi.org/10.1016/j.ejphar.2008.10.002>
31. Liu WH, Liu TC, Yin MC (2008) Beneficial effects of histidine and carnosine on ethanol-induced chronic liver injury. *Food Chem Toxicol* 46: 1503–1509. <https://doi.org/10.1016/j.fct.2007.12.013>
32. Mehmetçik G, Ozdemirler G, Koçak-Toker N, et al. (2008) Role of carnosine in preventing thioacetamide-induced liver injury in the rat. *Peptides* 29: 425–429. <https://doi.org/10.1016/j.peptides.2007.11.008>
33. Baykara B, Tekmen I, Pekcetin C, et al. (2009) The protective effects of carnosine and melatonin in ischemia-reperfusion injury in the rat liver. *Acta Histochem* 111: 42–51. <https://doi.org/10.1016/j.acthis.2008.03.002>
34. Yan SL, Wu ST, Yin MC, et al. (2009) Protective effects from carnosine and histidine on acetaminophen-induced liver injury. *J Food Sci* 74: H259–265. <https://doi.org/10.1111/j.1750-3841.2009.01330.x>
35. Fouad AA, Qureshi HA, Yacoubi MT, et al. (2009) Protective role of carnosine in mice with cadmium-induced acute hepatotoxicity. *Food Chem Toxicol* 47: 2863–2870. <https://doi.org/10.1016/j.fct.2009.09.009>
36. Kamal MA, Jiang H, Hu Y, et al. (2009) Influence of genetic knockout of Pept2 on the in vivo disposition of endogenous and exogenous carnosine in wild-type and Pept2 null mice. *Am J Physiol Regul Integr Comp Physiol* 296: R986–991. <https://doi.org/10.1152/ajpregu.90744.2008>
37. Renner C, Zemitzsch N, Fuchs B, et al. (2010) Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. *Mol Cancer* 9: 1–7. <https://doi.org/10.1186/1476-4598-9-2>
38. Ozel Turkcu U, Bilgihan A, Biberoglu G, et al. (2010) Carnosine supplementation protects rat brain tissue against ethanol-induced oxidative stress. *Mol Cell Biochem* 339: 55–61. <https://doi.org/10.1007/s11010-009-0369-x>
39. Aydin AF, Küçükgergin C, Ozdemirler-Erata G, et al. (2010) The effect of carnosine treatment on prooxidant-antioxidant balance in liver, heart and brain tissues of male aged rats. *Biogerontology* 11: 103–109. <https://doi.org/10.1007/s10522-009-9232-4>
40. Aydin AF, Küskü-Kiraz Z, Doğru-Abbasoğlu S, et al. (2010) Effect of carnosine against thioacetamide-induced liver cirrhosis in rat. *Peptides* 31: 67–71. <https://doi.org/10.1016/j.peptides.2009.11.028>
41. Artun BC, Küskü-Kiraz Z, Güllüoğlu M, et al. (2010) The effect of carnosine pretreatment on oxidative stress and hepatotoxicity in binge ethanol administered rats. *Hum Exp Toxicol* 29: 659–665. <https://doi.org/10.1177/0960327109359460>
42. Riedl E, Pfister F, Braunagel M, et al. (2011) Carnosine prevents apoptosis of glomerular cells and podocyte loss in STZ diabetic rats. *Cell Physiol Biochem* 28: 279–288. <https://doi.org/10.1159/000331740>

43. Aldini G, Orioli M, Rossoni G, et al. (2011) The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats. *J Cell Mol Med* 15: 1339–1354. <https://doi.org/10.1111/j.1582-4934.2010.01101.x>
44. Tsoi B, He RR, Yang DH, et al. (2011) Carnosine ameliorates stress-induced glucose metabolism disorder in restrained mice. *J Pharmacol Sci* 117: 223–229. <https://doi.org/10.1254/jphs.11131fp>
45. Mong MC, Chao CY, Yin MC (2011) Histidine and carnosine alleviated hepatic steatosis in mice consumed high saturated fat diet. *Eur J Pharmacol* 653: 82–88. <https://doi.org/10.1016/j.ejphar.2010.12.001>
46. Li YF, He RR, Tsoi B, et al. (2012) Anti-stress effects of carnosine on restraint-evoked immunocompromise in mice through spleen lymphocyte number maintenance. *PLoS One* 7: e33190. <https://doi.org/10.1371/journal.pone.0033190>
47. Menini S, Iacobini C, Ricci C, et al. (2012) D-Carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. *Br J Pharmacol* 166: 1344–1356. <https://doi.org/10.1111/j.1476-5381.2012.01834.x>
48. Peters V, Schmitt CP, Zschocke J, et al. (2012) Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. *Amino Acids* 42: 2411–2416. <https://doi.org/10.1007/s00726-011-1046-4>
49. Ansurudeen I, Sunkari VG, Grünler J, et al. (2012) Carnosine enhances diabetic wound healing in the db/db mouse model of type 2 diabetes. *Amino Acids* 43: 127–134. <https://doi.org/10.1007/s00726-012-1269-z>
50. Barski OA, Xie Z, Baba SP, et al. (2013) Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice. *Arterioscler Thromb Vasc Biol* 33: 1162–1170. <https://doi.org/10.1161/ATVBAHA.112.300572>
51. Everaert I, Stegen S, Vanheel B, et al. (2013) Effect of beta-alanine and carnosine supplementation on muscle contractility in mice. *Med Sci Sports Exerc* 45: 43–51. <https://doi.org/10.1249/MSS.0b013e31826cdb68>
52. Sahin S, Oter S, Burukoğlu D, et al. (2013) The effects of carnosine in an experimental rat model of septic shock. *Med Sci Monit Basic Res* 19: 54–61. <https://doi.org/10.12659/msmbr.883758>
53. Kalaz EB, Çoban J, Aydin AF, et al. (2014) Carnosine and taurine treatments decreased oxidative stress and tissue damage induced by D-galactose in rat liver. *J Physiol Biochem* 70: 15–25. <https://doi.org/10.1007/s13105-013-0275-2>
54. Giriş M, Doğru-Abbasoğlu S, Kumral A, et al. (2014) Effect of carnosine alone or combined with α-tocopherol on hepatic steatosis and oxidative stress in fructose-induced insulin-resistant rats. *J Physiol Biochem* 70: 385–395. <https://doi.org/10.1007/s13105-014-0314-7>
55. Macarini JR, Maravai SG, Cararo JH, et al. (2014) Impairment of electron transfer chain induced by acute carnosine administration in skeletal muscle of young rats. *Biomed Res Int* 2014: 632986. <https://doi.org/10.1155/2014/632986>
56. Brown BE, Kim CH, Torpy FR, et al. (2014) Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apo E (-/-) mice. *Atherosclerosis* 232: 403–409. <https://doi.org/10.1016/j.atherosclerosis.2013.11.068>
57. Evran B, Karpuzoğlu H, Develi S, et al. (2014) Effects of carnosine on prooxidant-antioxidant status in heart tissue, plasma and erythrocytes of rats with isoproterenol-induced myocardial infarction. *Pharmacol Rep* 66: 81–86. <https://doi.org/10.1016/j.pharep.2013.08.008>

58. Peters V, Riedl E, Braunagel M, et al. (2014) Carnosine treatment in combination with ACE inhibition in diabetic rats. *Regul Pept* 194–195: 36–40. <https://doi.org/10.1016/j.regpep.2014.09.005>

59. Bao Y, Gao C, Hao W, et al. (2015) Effects of Dietary L-carnosine and Alpha-lipoic Acid on Growth Performance, Blood Thyroid Hormones and Lipid Profiles in Finishing Pigs. *Asian-Australas J Anim Sci* 28: 1465–1470. <https://doi.org/10.5713/ajas.14.0604>

60. Stegen S, Stegen B, Aldini G, et al. (2015) Plasma carnosine, but not muscle carnosine, attenuates high-fat diet-induced metabolic stress. *Appl Physiol Nutr Metab* 40: 868–876. <https://doi.org/10.1139/apnm-2015-0042>

61. Forsberg EA, Botusan IR, Wang J, et al. (2015) Carnosine decreases IGFBP1 production in db/db mice through suppression of HIF-1. *J Endocrinol* 225: 159–167. <https://doi.org/10.1530/joe-14-0571>

62. Wu T, Tao Y, Tsang F, et al. (2015) The effect of L-carnosine on the circadian resetting of clock genes in the heart of rats. *Mol Biol Rep* 42: 87–94. <https://doi.org/10.1007/s11033-014-3745-x>

63. Menini S, Iacobini C, Ricci C, et al. (2015) Protection from diabetes-induced atherosclerosis and renal disease by D-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice. *Diabetologia* 58: 845–853. <https://doi.org/10.1007/s00125-014-3467-6>

64. Alsheblak MM, Elsherbiny NM, El-Karef A, et al. (2016) Protective effects of L-carnosine on CCl4 -induced hepatic injury in rats. *Eur Cytokine Netw* 27: 6–15. <https://doi.org/10.1684/ecn.2016.0372>

65. Ahshin-Majd S, Zamani S, Kiamari T, et al. (2016) Carnosine ameliorates cognitive deficits in streptozotocin-induced diabetic rats: Possible involved mechanisms. *Peptides* 86: 102–111. <https://doi.org/10.1016/j.peptides.2016.10.008>

66. Milewski K, Hilgier W, Fręsko I, et al. (2016) Carnosine Reduces Oxidative Stress and Reverses Attenuation of Righting and Postural Reflexes in Rats with Thioacetamide-Induced Liver Failure. *Neurochem Res* 41: 376–384. <https://doi.org/10.1007/s11064-015-1821-9>

67. Kumral A, Giriş M, Soluk-Tekkeşin M, et al. (2016) Beneficial effects of carnosine and carnosine plus vitamin E treatments on doxorubicin-induced oxidative stress and cardiac, hepatic, and renal toxicity in rats. *Hum Exp Toxicol* 35: 635–643. <https://doi.org/10.1177/0960327115597468>

68. Hasanein P, Kazemian-Mahtaj A, Khodadadi I (2016) Bioactive peptide carnosin protects against lead acetate-induced hepatotoxicity by abrogation of oxidative stress in rats. *Pharm Biol* 54: 1458–1464. <https://doi.org/10.3109/13880209.2015.1104700>

69. Hasanein P, Teimuri-Far M (2015) Protective effect of bioactive peptide carnosine against lead-induced oxidative stress in kidney of rats. *Cell Mol Biol (Noisy-le-grand)* 61: 8–14.

70. Fouad AA, Qutub HO, Al Rashed AS, et al. (2017) Therapeutic effect of carnosine in rat model of experimental liver carcinogenesis. *Environ Toxicol Pharmacol* 56: 10–14. <https://doi.org/10.1016/j.etap.2017.08.021>

71. Sun C, Wu Q, Zhang X, et al. (2017) Mechanistic Evaluation of the Protective Effect of Carnosine on Acute Lung Injury in Sepsis Rats. *Pharmacology* 100: 292–300. <https://doi.org/10.1159/000479879>

72. Albrecht T, Schilperoort M, Zhang S, et al. (2017) Carnosine Attenuates the Development of both Type 2 Diabetes and Diabetic Nephropathy in BTBR ob/ob Mice. *Sci Rep* 7: 44492. <https://doi.org/10.1038/srep44492>

73. Aydin AF, Bingül İ, Küçükgergin C, et al. (2017) Carnosine decreased oxidation and glycation products in serum and liver of high-fat diet and low-dose streptozotocin-induced diabetic rats. *Int J Exp Pathol* 98: 278–288. <https://doi.org/10.1111/iep.12252>

74. Fatih Aydin A, Küçükgergin C, Bingül İ, et al. (2017) Effect of Carnosine on Renal Function, Oxidation and Glycation Products in the Kidneys of High-Fat Diet/Streptozotocin-Induced Diabetic Rats. *Exp Clin Endocrinol Diabetes* 125: 282–289. <https://doi.org/10.1055/s-0043-100117>

75. Sahin S, Burukoglu Donmez D (2018) Effects of Carnosine (Beta-Alanyl-L-Histidine) in an Experimental Rat Model of Acute Kidney Injury Due to Septic Shock. *Med Sci Monit* 24: 305–316. <https://doi.org/10.12659/msm.905181>

76. Iacobini C, Menini S, Blasetti Fantauzzi C, et al. (2018) FL-926-16, a novel bioavailable carnosinase-resistant carnosine derivative, prevents onset and stops progression of diabetic nephropathy in db/db mice. *Br J Pharmacol* 175: 53–66. <https://doi.org/10.1111/bph.14070>

77. Deng J, Zhong YF, Wu YP, et al. (2018) Carnosine attenuates cyclophosphamide-induced bone marrow suppression by reducing oxidative DNA damage. *Redox Biol* 14: 1–6. <https://doi.org/10.1016/j.redox.2017.08.003>

78. Abplanalp W, Haberzettl P, Bhatnagar A, et al. (2019) Carnosine Supplementation Mitigates the deleterious Effects of Particulate Matter Exposure in Mice. *J Am Heart Assoc* 8: e013041. <https://doi.org/10.1161/jaha.119.013041>

79. Liu XQ, Jiang L, Lei L, et al. (2020) Carnosine alleviates diabetic nephropathy by targeting GNMT, a key enzyme mediating renal inflammation and fibrosis. *Clin Sci (Lond)* 134: 3175–3193. <https://doi.org/10.1042/cs20201207>

80. Zhao J, Conklin DJ, Guo Y, et al. (2020) Cardiospecific Overexpression of ATPGD1 (Carnosine Synthase) Increases Histidine Dipeptide Levels and Prevents Myocardial Ischemia Reperfusion Injury. *J Am Heart Assoc* 9: e015222. <https://doi.org/10.1161/jaha.119.015222>

81. Everaert I, He J, Hanssens M, et al. (2020) Carnosinase-1 overexpression, but not aerobic exercise training, affects the development of diabetic nephropathy in BTBR ob/ob mice. *Am J Physiol Renal Physiol* 318: F1030–f1040. <https://doi.org/10.1152/ajprenal.00329.2019>

82. Qiu J, Albrecht T, Zhang S, et al. (2020) Human carnosinase 1 overexpression aggravates diabetes and renal impairment in BTBR(Ob/Ob) mice. *J Mol Med (Berl)* 98: 1333–1346. <https://doi.org/10.1007/s00109-020-01957-0>

83. Weigand T, Colbatzky F, Pfeffer T, et al. (2020) A Global Cndp1-Knock-Out Selectively Increases Renal Carnosine and Anserine Concentrations in an Age- and Gender-Specific Manner in Mice. *Int J Mol Sci* 21: 4887. <https://doi.org/10.3390/ijms21144887>

84. Ommati MM, Farshad O, Ghanbarinejad V, et al. (2020) The Nephroprotective Role of Carnosine Against Ifosfamide-Induced Renal Injury and Electrolytes Imbalance is Mediated Via the Regulation of Mitochondrial Function and Alleviation of Oxidative Stress. *Drug Res (Stuttg)* 70: 49–56. <https://doi.org/10.1055/a-1017-5085>

85. Yaqub LS, Ayo JO, Habibu B, et al. (2021) Thermoregulatory, oxidative stress and lipid responses in prepartum ewes administered with L-carnosine during the hot-dry season. *Trop Anim Health Prod* 53: 388. <https://doi.org/10.1007/s11250-021-02832-x>

86. Stefani GP, Capalonga L, da Silva LR, et al. (2021) Effects of aerobic and resistance exercise training associated with carnosine precursor supplementation on maximal strength and VO(2max) in rats with heart failure. *Life Sci* 282: 119816. <https://doi.org/10.1016/j.lfs.2021.119816>

87. Riger NA, Trushina EN, Mustafina OK, et al. (2021) [Pathogenetic mechanisms for the development of hematological disorders in induced fatty liver disease in Wistar rats and assessment of the regulatory effects of carnosine and α -lipoic acid]. *Vopr Pitan* 90: 6–19. <https://doi.org/10.33029/0042-8833-2021-90-3-6-19>

88. Gonçalves LS, Sales LP, Saito TR, et al. (2021) Histidine dipeptides are key regulators of excitation-contraction coupling in cardiac muscle: Evidence from a novel CARNS1 knockout rat model. *Redox Biol* 44: 102016. <https://doi.org/10.1016/j.redox.2021.102016>

89. Schwank-Xu C, Forsberg E, Bentinger M, et al. (2021) L-Carnosine Stimulation of Coenzyme Q10 Biosynthesis Promotes Improved Mitochondrial Function and Decreases Hepatic Steatosis in Diabetic Conditions. *Antioxidants (Basel)* 10: 793. <https://doi.org/10.3390/antiox10050793>

90. Nooh MM, Rizk SM, Saied NM, et al. (2021) Carnosine Remedial Effect on Fertility of Male Rats Receiving Cyclophosphamide, Hydroxydaunomycin, Oncovin and Prednisone (CHOP). *Andrologia* 53: e14233. <https://doi.org/10.1111/and.14233>

91. Zhu W, Li YY, Zeng HX, et al. (2021) Carnosine alleviates podocyte injury in diabetic nephropathy by targeting caspase-1-mediated pyroptosis. *Int Immunopharmacol* 101: 108236. <https://doi.org/10.1016/j.intimp.2021.108236>

92. Busa P, Lee SO, Huang N, et al. (2022) Carnosine Alleviates Knee Osteoarthritis and Promotes Synoviocyte Protection via Activating the Nrf2/HO-1 Signaling Pathway: An In-Vivo and In-Vitro Study. *Antioxidants (Basel)* 11: 1209. <https://doi.org/10.3390/antiox11061209>

93. Rodriguez-Niño A, Pastene DO, Hettler SA, et al. (2022) Influence of carnosine and carnosinase-1 on diabetes-induced afferent arteriole vasodilation: implications for glomerular hemodynamics. *Am J Physiol Renal Physiol* 323: F69–F80. <https://doi.org/10.1152/ajprenal.00232.2021>

94. Park J, Jang J, Cha SR, et al. (2022) L-carnosine Attenuates Bleomycin-Induced Oxidative Stress via NF κ B Pathway in the Pathogenesis of Pulmonary Fibrosis. *Antioxidants (Basel)* 11: 2462. <https://doi.org/10.3390/antiox11122462>

95. Zharikov AY, Kalnitsky AS, Mazko ON, et al. (2023) Effect of Carnosine on the Activity of Matrix Metalloproteinase-2 and Oxidative Stress in the Kidneys in Experimental Urate Nephrolithiasis. *Bull Exp Biol Med* 174: 326–329. <https://doi.org/10.1007/s10517-023-05701-9>

96. Ommati MM, Sabouri S, Niknahad H, et al. (2023) Pulmonary inflammation, oxidative stress, and fibrosis in a mouse model of cholestasis: the potential protective properties of the dipeptide carnosine. *Naunyn Schmiedebergs Arch Pharmacol* 396: 1129–1142. <https://doi.org/10.1007/s00210-023-02391-y>

97. Zhang S, Li Y, Liu X, et al. (2023) Carnosine alleviates kidney tubular epithelial injury by targeting NRF2 mediated ferroptosis in diabetic nephropathy. *Amino Acids* 55: 1141–1155. <https://doi.org/10.1007/s00726-023-03301-5>

98. Rathor R, Srivastava S, Suryakumar G (2023) A Comparative Biochemical Study Between L-Carnosine and beta-Alanine in Amelioration of Hypobaric Hypoxia-Induced Skeletal Muscle Protein Loss. *High Alt Med Biol* 24: 302–311. <https://doi.org/10.1089/ham.2023.0014>

99. Luo X, Li Y, Wang B, et al. (2023) Carnosine alleviates cisplatin-induced acute kidney injury by targeting Caspase-1 regulated pyroptosis. *Biomed Pharmacother* 167: 115563. <https://doi.org/10.1016/j.bioph.2023.115563>

100. Berdaweeil IA, Monroe TB, Alowaisi AA, et al. (2023) Iron scavenging and suppression of collagen cross-linking underlie antifibrotic effects of carnosine in the heart with obesity. *Front Pharmacol* 14: 1275388. <https://doi.org/10.3389/fphar.2023.1275388>

101. Moreto F, Garcia JL, Ferreira A, et al. (2024) Quantitative proteomics study of carnosine effect in an animal model of Western diet-induced nonalcoholic fatty liver disease. *J Biochem Mol Toxicol* 38: e23644. <https://doi.org/10.1002/jbt.23644>

102. Grandini NA, Costa MR, Gregolin CS, et al. (2024) Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model. *Mol Cell Endocrinol* 582: 112138. <https://doi.org/10.1016/j.mce.2023.112138>

103. D'Amato A, Altomare A, Gilardoni E, et al. (2024) A quantitative proteomic approach to evaluate the efficacy of carnosine in a murine model of chronic obstructive pulmonary disease (COPD). *Redox Biol* 77: 103374. <https://doi.org/10.1016/j.redox.2024.103374>

104. Drenjančević I, Stupin A, Jukić I, et al. (2024) Oral Carnosine Supplementation Preserves Vascular Function of Sprague Dawley Rats on a High-Salt Diet via Restored Antioxidative Defence. *Nutrients* 17: 36. <https://doi.org/10.3390/nu17010036>

105. Xu X, Pastene DO, Qiu J, et al. (2025) Influence of carnosine supplementation on disease progression in a rat model of focal segmental glomerulosclerosis. *Am J Physiol Renal Physiol* 328: F599–f607. <https://doi.org/10.1152/ajprenal.00017.2024>

106. Meng Y, Xian T, Kang G, et al. (2024) Effects of dietary l-carnosine supplementation on the growth, intestinal microbiota, and serum metabolome of fattening lambs. *Front Vet Sci* 11: 1525783. <https://doi.org/10.3389/fvets.2024.1525783>

107. Li XY, Gu XY, Li XM, et al. (2025) Supplementation with carnosine, a food-derived bioactive dipeptide, alleviates dexamethasone-induced oxidative stress and bone impairment via the NRF2 signaling pathway. *J Sci Food Agric* 105: 1091–1104. <https://doi.org/10.1002/jsfa.13899>

108. Tomonaga S, Tachibana T, Takagi T, et al. (2004) Effect of central administration of carnosine and its constituents on behaviors in chicks. *Brain Res Bull* 63: 75–82. <https://doi.org/10.1016/j.brainresbull.2004.01.002>

109. Tomonaga S, Tachibana T, Takahashi H, et al. (2005) Nitric oxide involves in carnosine-induced hyperactivity in chicks. *Eur J Pharmacol* 524: 84–88. <https://doi.org/10.1016/j.ejphar.2005.09.008>

110. Zemke D, Krishnamurthy R, Majid A (2005) Carnosine is neuroprotective in a mouse model of stroke. *J Cereb Blood Flow Metab* 25: S313–S313. <https://doi.org/10.1038/sj.jcbfm.9591524.0313>

111. Fedorova TN, Macletsova MG, Kulikov AV, et al. (2006) Carnosine protects from the oxidative stress induced by prenatal hypoxia. *Dokl Biol Sci* 408: 207–210. <https://doi.org/10.1134/s001249660603001x>

112. Dobrota D, Fedorova T, Stvolinsky S, et al. (2005) Carnosine protects the brain of rats and Mongolian gerbils against ischemic injury: after-stroke-effect. *Neurochem Res* 30: 1283–1288. <https://doi.org/10.1007/s11064-005-8799-7>

113. Jin CL, Yang LX, Wu XH, et al. (2005) Effects of carnosine on amygdaloid-kindled seizures in Sprague-Dawley rats. *Neuroscience* 135: 939–947. <https://doi.org/10.1016/j.neuroscience.2005.06.066>

114. Wu XH, Ding MP, Zhu-Ge ZB, et al. (2006) Carnosine, a precursor of histidine, ameliorates pentylenetetrazole-induced kindled seizures in rat. *Neurosci Lett* 400: 146–149. <https://doi.org/10.1016/j.neulet.2006.02.031>

115. Tsuneyoshi Y, Tomonaga S, Asechi M, et al. (2007) Central administration of dipeptides, beta-alanyl-BCAAs, induces hyperactivity in chicks. *BMC Neurosci* 8: 37. <https://doi.org/10.1186/1471-2202-8-37>

116. Rajanikant GK, Zemke D, Senut MC, et al. (2007) Carnosine is neuroprotective against permanent focal cerebral ischemia in mice. *Stroke* 38: 3023–3031. <https://doi.org/10.1161/strokeaha.107.488502>

117. Zhu YY, Zhu-Ge ZB, Wu DC, et al. (2007) Carnosine inhibits pentylenetetrazol-induced seizures by histaminergic mechanisms in histidine decarboxylase knock-out mice. *Neurosci Lett* 416: 211–216. <https://doi.org/10.1016/j.neulet.2007.01.075>

118. Tanida M, Gotoh H, Taniguchi H, et al. (2007) Effects of central injection of L-carnosine on sympathetic nerve activity innervating brown adipose tissue and body temperature in rats. *Regul Pept* 144: 62–71. <https://doi.org/10.1016/j.regpep.2007.06.001>

119. Tomonaga S, Yamane H, Onitsuka E, et al. (2008) Carnosine-induced antidepressant-like activity in rats. *Pharmacol Biochem Behav* 89: 627–632. <https://doi.org/10.1016/j.pbb.2008.02.021>

120. Min J, Senut MC, Rajanikant K, et al. (2008) Differential neuroprotective effects of carnosine, anserine, and N-acetyl carnosine against permanent focal ischemia. *J Neurosci Res* 86: 2984–2991. <https://doi.org/10.1002/jnr.21744>

121. Derave W, Jones G, Hespel P, et al. (2008) Creatine supplementation augments skeletal muscle carnosine content in senescence-accelerated mice (SAMP8). *Rejuvenation Res* 11: 641–647. <https://doi.org/10.1089/rej.2008.0699>

122. Kozan R, Sefil F, Bağırıcı F (2008) Anticonvulsant effect of carnosine on penicillin-induced epileptiform activity in rats. *Brain Res* 1239: 249–255. <https://doi.org/10.1016/j.brainres.2008.08.019>

123. Pekcetin C, Kiray M, Ergur BU, et al. (2009) Carnosine attenuates oxidative stress and apoptosis in transient cerebral ischemia in rats. *Acta Biol Hung* 60: 137–148. <https://doi.org/10.1556/ABiol.60.2009.2.1>

124. Feng ZY, Zheng XJ, Wang J (2009) Effects of carnosine on the evoked potentials in hippocampal CA1 region. *J Zhejiang Univ Sci B* 10: 505–511. <https://doi.org/10.1631/jzus.B0820370>

125. Aydín AF, Küskü-Kiraz Z, Doğru-Abbasoğlu S, et al. (2010) Effect of carnosine treatment on oxidative stress in serum, apoB-containing lipoproteins fraction and erythrocytes of aged rats. *Pharmacol Rep* 62: 733–739. [https://doi.org/10.1016/s1734-1140\(10\)70331-5](https://doi.org/10.1016/s1734-1140(10)70331-5)

126. Shen Y, He P, Fan YY, et al. (2010) Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicity. *Free Radic Biol Med* 48: 727–735. <https://doi.org/10.1016/j.freeradbiomed.2009.12.021>

127. Tsai SJ, Kuo WW, Liu WH, et al. (2010) Antioxidative and anti-inflammatory protection from carnosine in the striatum of MPTP-treated mice. *J Agric Food Chem* 58: 11510–11516. <https://doi.org/10.1021/jf103258p>

128. Zhang X, Song L, Cheng X, et al. (2011) Carnosine pretreatment protects against hypoxia-ischemia brain damage in the neonatal rat model. *Eur J Pharmacol* 667: 202–207. <https://doi.org/10.1016/j.ejphar.2011.06.003>

129. Di Paola R, Impellizzeri D, Salinaro AT, et al. (2011) Administration of carnosine in the treatment of acute spinal cord injury. *Biochem Pharmacol* 82: 1478–1489. <https://doi.org/10.1016/j.bcp.2011.07.074>

130. Corona C, Frazzini V, Silvestri E, et al. (2011) Effects of dietary supplementation of carnosine on mitochondrial dysfunction, amyloid pathology, and cognitive deficits in 3xTg-AD mice. *PLoS One* 6: e17971. <https://doi.org/10.1371/journal.pone.0017971>

131. Faddah L, Baky NAA, Al-Rasheed NM, et al. (2012) Carnosine and cyclosporine A alleviate brain damage after traumatic brain injury in rats. *Afr J Pharm Pharmacol* 6: 3305–3312. <https://doi.org/10.5897/AJPP12.533>

132. Ma J, Chen J, Bo S, et al. (2015) Protective effect of carnosine after chronic cerebral hypoperfusion possibly through suppressing astrocyte activation. *Am J Transl Res* 7: 2706–2715.

133. Ma J, Xiong JY, Hou WW, et al. (2012) Protective effect of carnosine on subcortical ischemic vascular dementia in mice. *CNS Neurosci Ther* 18: 745–753. <https://doi.org/10.1111/j.1755-5949.2012.00362.x>

134. Coban J, Bingül I, Yesil-Mizrak K, et al. (2013) Effects of carnosine plus vitamin E and betaine treatments on oxidative stress in some tissues of aged rats. *Curr Aging Sci* 6: 199–205. <https://doi.org/10.2174/18746098112059990011>

135. Herculano B, Tamura M, Ohba A, et al. (2013) β -alanyl-L-histidine rescues cognitive deficits caused by feeding a high fat diet in a transgenic mouse model of Alzheimer's disease. *J Alzheimers Dis* 33: 983–997. <https://doi.org/10.3233/jad-2012-121324>

136. Wang JP, Yang ZT, Liu C, et al. (2013) L-carnosine inhibits neuronal cell apoptosis through signal transducer and activator of transcription 3 signaling pathway after acute focal cerebral ischemia. *Brain Res* 1507: 125–133. <https://doi.org/10.1016/j.brainres.2013.02.032>

137. Bae ON, Majid A (2013) Role of histidine/histamine in carnosine-induced neuroprotection during ischemic brain damage. *Brain Res* 1527: 246–254. <https://doi.org/10.1016/j.brainres.2013.07.004>

138. Bae ON, Serfozo K, Baek SH, et al. (2013) Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke. *Stroke* 44: 205–212. <https://doi.org/10.1161/strokeaha.112.673954>

139. Park HS, Han KH, Shin JA, et al. (2014) The neuroprotective effects of carnosine in early stage of focal ischemia rodent model. *J Korean Neurosurg Soc* 55: 125–130. <https://doi.org/10.3340/jkns.2014.55.3.125>

140. Zhang H, Guo S, Zhang L, et al. (2014) Treatment with carnosine reduces hypoxia-ischemia brain damage in a neonatal rat model. *Eur J Pharmacol* 727: 174–180. <https://doi.org/10.1016/j.ejphar.2014.01.023>

141. Ji YS, Park JW, Heo H, et al. (2014) The neuroprotective effect of carnosine (β -alanyl-L-histidine) on retinal ganglion cell following ischemia-reperfusion injury. *Curr Eye Res* 39: 634–641. <https://doi.org/10.3109/02713683.2013.855235>

142. Inozemtsev AN, Berezhnoy DS, Fedorova TN, et al. (2014) The effect of the natural dipeptide carnosine on learning of rats under the conditions of negative reinforcement. *Dokl Biol Sci* 454: 16–18. <https://doi.org/10.1134/s0012496614010177>

143. Albayrak S, Atci İ B, Kalayci M, et al. (2015) Effect of carnosine, methylprednisolone and their combined application on irisin levels in the plasma and brain of rats with acute spinal cord injury. *Neuropeptides* 52: 47–54. <https://doi.org/10.1016/j.npep.2015.06.004>

144. Dai YJ, Wu DC, Feng B, et al. (2015) Protective effect of carnosine on febrile seizures in immature mice. *Neurosci Lett* 588: 95–100. <https://doi.org/10.1016/j.neulet.2014.12.061>

145. Macedo LW, Cararo JH, Maravai SG, et al. (2016) Acute Carnosine Administration Increases Respiratory Chain Complexes and Citric Acid Cycle Enzyme Activities in Cerebral Cortex of Young Rats. *Mol Neurobiol* 53: 5582–5590. <https://doi.org/10.1007/s12035-015-9475-9>

146. Russo R, Adornetto A, Cavalieri F, et al. (2015) Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury. *Mol Vis* 21: 718–729.

147. Zhang ZY, Sun BL, Yang MF, et al. (2015) Carnosine attenuates early brain injury through its antioxidative and anti-apoptotic effects in a rat experimental subarachnoid hemorrhage model. *Cell Mol Neurobiol* 35: 147–157. <https://doi.org/10.1007/s10571-014-0106-1>

148. Afshin-Majd S, Khalili M, Roghani M, et al. (2015) Carnosine exerts neuroprotective effect against 6-hydroxydopamine toxicity in hemiparkinsonian rat. *Mol Neurobiol* 51: 1064–1070. <https://doi.org/10.1007/s12035-014-8771-0>

149. Aydin AF, Çoban J, Doğan-Ekici I, et al. (2016) Carnosine and taurine treatments diminished brain oxidative stress and apoptosis in D-galactose aging model. *Metab Brain Dis* 31: 337–345. <https://doi.org/10.1007/s11011-015-9755-0>

150. Ma J, Bo SH, Lu XT, et al. (2016) Protective effects of carnosine on white matter damage induced by chronic cerebral hypoperfusion. *Neural Regen Res* 11: 1438–1444. <https://doi.org/10.4103/1673-5374.191217>

151. Baky NA, Fadda L, Al-Rasheed NM, et al. (2016) Neuroprotective effect of carnosine and cyclosporine-A against inflammation, apoptosis, and oxidative brain damage after closed head injury in immature rats. *Toxicol Mech Methods* 26: 1–10. <https://doi.org/10.3109/15376516.2015.1070224>

152. Banerjee S, Poddar MK (2016) Aging-induced changes in brain regional serotonin receptor binding: Effect of Carnosine. *Neuroscience* 319: 79–91. <https://doi.org/10.1016/j.neuroscience.2016.01.032>

153. Al-Rasheed NM, Fadda L, Mohamed AM, et al. (2016) Regulating effect of carnosine and/or l-arginine on the expression of inflammatory molecules induced nephropathy in the hypoxic rat model. *Braz Arch Biol Technol* 59: e16150622. <https://doi.org/10.1590/1678-4324-2016150622>

154. Kaneko J, Enya A, Enomoto K, et al. (2017) Anserine (beta-alanyl-3-methyl-L-histidine) improves neurovascular-unit dysfunction and spatial memory in aged A β PPswe/PSEN1dE9 Alzheimer's-model mice. *Sci Rep* 7: 12571. <https://doi.org/10.1038/s41598-017-12785-7>

155. Zhao J, Shi L, Zhang LR (2017) Neuroprotective effect of carnosine against salsolinol-induced Parkinson's disease. *Exp Ther Med* 14: 664–670. <https://doi.org/10.3892/etm.2017.4571>

156. Keskin A, Kanar BG, Kanar RG, et al. (2017) An investigation on the impact of carnosine on the myocardium in lower extremity ischemia-reperfusion injury in rats. *Int J Cardiovasc Acad* 3: 109–113. <https://doi.org/10.1016/j.ijcac.2016.11.054>

157. Stvolinsky SL, Fedorova TN, Devyatov AA, et al. (2017) [A neuroprotective action of carnosine in conditions of experimental focal cerebral ischemia-reperfusion]. *Zh Nevrol Psichiatr Im S S Korsakova* 117: 60–64. <https://doi.org/10.17116/jnevro201711712260-64>

158. Xie RX, Li DW, Liu XC, et al. (2017) Carnosine Attenuates Brain Oxidative Stress and Apoptosis After Intracerebral Hemorrhage in Rats. *Neurochem Res* 42: 541–551. <https://doi.org/10.1007/s11064-016-2104-9>

159. Aydin F, Kalaz EB, Kucukgergin C, et al. (2018) Carnosine Treatment Diminished Oxidative Stress and Glycation Products in Serum and Tissues of D-Galactose-Treated Rats. *Curr Aging Sci* 11: 10–15. <https://doi.org/10.2174/1871530317666170703123519>

160. Devyatov AA, Fedorova TN, Stvolinsky SL, et al. (2018) [Study of the neuroprotective effects of carnosine in an experimental model of focal cerebral ischemia/reperfusion]. *Biomed Khim* 64: 344–348. <https://doi.org/10.18097/pbmc20186404344>

161. Fedorova TN, Devyatov AA, Berezhnoi DS, et al. (2018) Oxidative Status in Different Areas of the Cerebral Cortex of Wistar Rats during Focal Ischemia and Its Modulation with Carnosine. *Bull Exp Biol Med* 165: 746–750. <https://doi.org/10.1007/s10517-018-4256-x>

162. Wang AH, Ma Q, Wang X, et al. (2018) Protective effects of beef decoction rich in carnosine on cerebral ischemia injury by permanent middle cerebral artery occlusion in rats. *Exp Ther Med* 15: 1321–1329. <https://doi.org/10.3892/etm.2017.5524>

163. Barca A, Gatti F, Spagnolo D, et al. (2018) Responsiveness of Carnosine Homeostasis Genes in the Pancreas and Brain of Streptozotocin-Treated Mice Exposed to Dietary Carnosine. *Int J Mol Sci* 19: 1713. <https://doi.org/10.3390/ijms19061713>

164. Qi Z, Yu X, Xu P, et al. (2018) L-Homocarnosine, L-carnosine, and anserine attenuate brain oxidative damage in a pentylenetetrazole-induced epilepsy model of ovariectomized rats. *3 Biotech* 8: 363. <https://doi.org/10.1007/s13205-018-1357-1>

165. Tiwari N, Bhatia P, Kumar A, et al. (2018) Potential of carnosine, a histamine precursor in rat model of bilateral common carotid artery occlusion-induced vascular dementia. *Fundam Clin Pharmacol* 32: 516–531. <https://doi.org/10.1111/fcp.12376>

166. Colín-Barenque L, Bizarro-Nevares P, González Villalva A, et al. (2018) Neuroprotective effect of carnosine in the olfactory bulb after vanadium inhalation in a mouse model. *Int J Exp Pathol* 99: 180–188. <https://doi.org/10.1111/iep.12285>

167. Bermúdez ML, Skelton MR, Genter MB (2018) Intranasal carnosine attenuates transcriptomic alterations and improves mitochondrial function in the Thy1-aSyn mouse model of Parkinson's disease. *Mol Genet Metab* 125: 305–313. <https://doi.org/10.1016/j.ymgme.2018.08.002>

168. Bermúdez ML, Seroogy KB, Genter MB (2019) Evaluation of Carnosine Intervention in the Thy1-aSyn Mouse Model of Parkinson's Disease. *Neuroscience* 411: 270–278. <https://doi.org/10.1016/j.neuroscience.2019.05.026>

169. Jain S, Kim ES, Kim D, et al. (2020) Comparative Cerebroprotective Potential of D- and L-Carnosine Following Ischemic Stroke in Mice. *Int J Mol Sci* 21: 3053. <https://doi.org/10.3390/ijms21093053>

170. Dai Z, Lu XY, Zhu WL, et al. (2020) Carnosine ameliorates age-related dementia via improving mitochondrial dysfunction in SAMP8 mice. *Food Funct* 11: 2489–2497. <https://doi.org/10.1039/c9fo02453k>

171. Ommati MM, Heidari R, Ghanbarinejad V, et al. (2020) The neuroprotective properties of carnosine in a mouse model of manganese is mediated via mitochondria regulating and antioxidative mechanisms. *Nutr Neurosci* 23: 731–743. <https://doi.org/10.1080/1028415x.2018.1552399>

172. Virdi JK, Bhanot A, Jaggi AS, et al. (2020) Investigation on beneficial role of L-carnosine in neuroprotective mechanism of ischemic postconditioning in mice: possible role of histidine histamine pathway. *Int J Neurosci* 130: 983–998. <https://doi.org/10.1080/00207454.2020.1715393>

173. Devyatov AA, Fedorova TN, Berezhnoi DS, et al. (2020) Mechanisms of Neuroprotective Action of Hesperetin and Carnosine in Focal Ischemia of the Brain in Rats. *Bull Exp Biol Med* 169: 242–245. <https://doi.org/10.1007/s10517-020-04859-w>

174. Attia H, Fadda L, Al-Rasheed N, et al. (2020) Carnosine and L-arginine attenuate the downregulation of brain monoamines and gamma aminobutyric acid; reverse apoptosis and upregulate the expression of angiogenic factors in a model of hemic hypoxia in rats. *Naunyn Schmiedebergs Arch Pharmacol* 393: 381–394. <https://doi.org/10.1007/s00210-019-01738-8>

175. Kim EH, Kim ES, Shin D, et al. (2021) Carnosine Protects against Cerebral Ischemic Injury by Inhibiting Matrix-Metalloproteinases. *Int J Mol Sci* 22: 7495. <https://doi.org/10.3390/ijms22147495>

176. Brown JM, Baker LS, Seroogy KB, et al. (2021) Intranasal Carnosine Mitigates α -Synuclein Pathology and Motor Dysfunction in the Thy1-aSyn Mouse Model of Parkinson's Disease. *ACS Chem Neurosci* 12: 2347–2359. <https://doi.org/10.1021/acschemneuro.1c00096>

177. Banerjee S, Mukherjee B, Poddar MK, et al. (2021) Carnosine improves aging-induced cognitive impairment and brain regional neurodegeneration in relation to the neuropathological alterations in the secondary structure of amyloid beta (A β). *J Neurochem* 158: 710–723. <https://doi.org/10.1111/jnc.15357>

178. Łochyński D, Pawlak M, Everaert I, et al. (2022) Motor Unit Fatigability following Chronic Carnosine Supplementation in Aged Rats. *Nutrients* 14: 514. <https://doi.org/10.3390/nu14030514>

179. Arslan A, Acer N, Kesici H, et al. (2022) Stereological Study on the Effect of Carnosine on of Purkinje Cells in the Cerebellum of Rats Exposed to 900 MHz Electromagnetic Field. *Turk Neurosurg* 32: 618–624. <https://doi.org/10.5137/1019-5149.JTN.35313-21.2>

180. Peng D, Xia Q, Guan L, et al. (2022) Carnosine Improves Cognitive Impairment Through Promoting SIRT6 Expression and Inhibiting Endoplasmic Reticulum Stress in a Diabetic Encephalopathy Model. *Rejuvenation Res* 25: 79–88. <https://doi.org/10.1089/rej.2022.0002>

181. Tsuji T, Furuhashi K, Gerasimenko M, et al. (2022) Oral Supplementation with L-Carnosine Attenuates Social Recognition Deficits in CD157KO Mice via Oxytocin Release. *Nutrients* 14: 803. <https://doi.org/10.3390/nu14040803>

182. Hegazy MA, Abdelmonsif DA, Zeitoun TM, et al. (2022) Swimming exercise versus L-carnosine supplementation for Alzheimer's dementia in rats: implication of circulating and hippocampal FNDC5/irisin. *J Physiol Biochem* 78: 109–124. <https://doi.org/10.1007/s13105-021-00845-6>

183. Ndolo RO, Yu L, Zhao Y, et al. (2023) Carnosine-Based Reversal of Diabetes-Associated Cognitive Decline via Activation of the Akt/mTOR Pathway and Modulation of Autophagy in a Rat Model of Type 2 Diabetes Mellitus. *Dement Geriatr Cogn Disord* 52: 156–168. <https://doi.org/10.1159/000530605>

184. Hu X, Fukui Y, Feng T, et al. (2023) Neuroprotective effects of carnosine in a mice stroke model concerning oxidative stress and inflammatory response. *J Neurol Sci* 447: 120608. <https://doi.org/10.1016/j.jns.2023.120608>

185. Rivi V, Caruso G, Caraci F, et al. (2024) Behavioral and transcriptional effects of carnosine in the central ring ganglia of the pond snail *Lymnaea stagnalis*. *J Neurosci Res* 102: e25371. <https://doi.org/10.1002/jnr.25371>

186. Shen J, Xu J, Wen Y, et al. (2024) Carnosine ameliorates postoperative cognitive dysfunction of aged rats by limiting astrocytes pyroptosis. *Neurotherapeutics* 21: e00359. <https://doi.org/10.1016/j.neurot.2024.e00359>

187. Chern H, Caruso G, Desaire H, et al. (2025) Carnosine Mitigates Cognitive Impairment and Dopamine Release in an Okadaic Acid-Induced Zebrafish Model with Alzheimer's Disease-like Symptoms. *ACS Chem Neurosci* 16: 790–801. <https://doi.org/10.1021/acschemneuro.4c00596>

188. Khama-Murad AX, Pavlinova LI, Mokrushin AA (2008) Neurotropic effect of exogenous L-carnosine in cultured slices of the olfactory cortex from rat brain. *Bull Exp Biol Med* 146: 1–3. <https://doi.org/10.1007/s10517-008-0227-y>

189. Solana-Manrique C, Sanz FJ, Martínez-Carrión G, et al. (2022) Antioxidant and Neuroprotective Effects of Carnosine: Therapeutic Implications in Neurodegenerative Diseases. *Antioxidants (Basel)* 11: 848. <https://doi.org/10.3390/antiox11050848>

190. Caruso G, Fresta CG, Musso N, et al. (2019) Carnosine Prevents Abeta-Induced Oxidative Stress and Inflammation in Microglial Cells: A Key Role of TGF-beta1. *Cells* 8: 64. <https://doi.org/10.3390/cells8010064>

191. Kubota M, Kobayashi N, Sugizaki T, et al. (2020) Carnosine suppresses neuronal cell death and inflammation induced by 6-hydroxydopamine in an in vitro model of Parkinson's disease. *PLoS One* 15: e0240448. <https://doi.org/10.1371/journal.pone.0240448>

192. Aloisi A, Barca A, Romano A, et al. (2013) Anti-aggregating effect of the naturally occurring dipeptide carnosine on abeta1-42 fibril formation. *PLoS One* 8: e68159. <https://doi.org/10.1371/journal.pone.0068159>

193. Attanasio F, Convertino M, Magno A, et al. (2013) Carnosine inhibits Abeta(42) aggregation by perturbing the H-bond network in and around the central hydrophobic cluster. *Chembiochem* 14: 583–592. <https://doi.org/10.1002/cbic.201200704>

194. Rivi V, Carota G, Tascedda F, et al. (2025) Carnosine modulates Aβ-induced transcriptional aberrations in murine microglial cells. *Curr Res Pharmacol Drug Discov* 8: 100221. <https://doi.org/10.1016/j.crphar.2025.100221>

195. Greco V, Naletova I, Ahmed IMM, et al. (2020) Hyaluronan-carnosine conjugates inhibit Aβ aggregation and toxicity. *Sci Rep* 10: 15998. <https://doi.org/10.1038/s41598-020-72989-2>

196. Distefano A, Caruso G, Oliveri V, et al. (2022) Neuroprotective Effect of Carnosine Is Mediated by Insulin-Degrading Enzyme. *ACS Chem Neurosci* 13: 1588–1593. <https://doi.org/10.1021/acschemneuro.2c00201>

197. Cardaci V, Di Pietro L, Zupan MC, et al. (2025) Characterizing oxidative stress induced by Abeta oligomers and the protective role of carnosine in primary mixed glia cultures. *Free Radic Biol Med* 229: 213–224. <https://doi.org/10.1016/j.freeradbiomed.2025.01.030>

198. Mizuno D, Kawahara M, Konoha-Mizuno K, et al. (2024) The Role of Zinc in the Development of Vascular Dementia and Parkinson's Disease and the Potential of Carnosine as Their Therapeutic Agent. *Biomedicines* 12: 1296. <https://doi.org/10.3390/biomedicines12061296>

199. Mizuno D, Konoha-Mizuno K, Mori M, et al. (2015) Protective activity of carnosine and anserine against zinc-induced neurotoxicity: a possible treatment for vascular dementia. *Metallomics* 7: 1233–1239. <https://doi.org/10.1039/c5mt00049a>

200. Kawahara M, Sadakane Y, Mizuno K, et al. (2020) Carnosine as a Possible Drug for Zinc-Induced Neurotoxicity and Vascular Dementia. *Int J Mol Sci* 21: 2570. <https://doi.org/10.3390/ijms21072570>

201. Khama-Murad A, Mokrushin AA, Pavlinova LI (2011) Neuroprotective properties of l-carnosine in the brain slices exposed to autolysis in the hemorrhagic stroke model in vitro. *Regul Pept* 167: 65–69. <https://doi.org/10.1016/j.regpep.2010.11.007>

202. Zhang L, Yao K, Fan Y, et al. (2012) Carnosine protects brain microvascular endothelial cells against rotenone-induced oxidative stress injury through histamine H₁ and H₂ receptors in vitro. *Clin Exp Pharmacol Physiol* 39: 1019–1025. <https://doi.org/10.1111/1440-1681.12019>

203. Takahashi S, Nakashima Y, Toda K (2009) Carnosine facilitates nitric oxide production in endothelial f-2 cells. *Biol Pharm Bull* 32: 1836–1839. <https://doi.org/10.1248/bpb.32.1836>

204. Spina-Purrello V, Giliberto S, Barresi V, et al. (2010) Modulation of PARP-1 and PARP-2 expression by L-carnosine and trehalose after LPS and INF γ -induced oxidative stress. *Neurochem Res* 35: 2144–2153. <https://doi.org/10.1007/s11064-010-0297-x>

205. Ou-Yang L, Liu Y, Wang BY, et al. (2018) Carnosine suppresses oxygen-glucose deprivation/recovery-induced proliferation and migration of reactive astrocytes of rats in vitro. *Acta Pharmacol Sin* 39: 24–34. <https://doi.org/10.1038/aps.2017.126>

206. Fresta CG, Hogard ML, Caruso G, et al. (2017) Monitoring carnosine uptake by RAW 264.7 macrophage cells using microchip electrophoresis with fluorescence detection. *Anal Methods* 9: 402–408. <https://doi.org/10.1039/C6AY03009B>

207. Fresta CG, Chakraborty A, Wijesinghe MB, et al. (2018) Non-toxic engineered carbon nanodiamond concentrations induce oxidative/nitrosative stress, imbalance of energy metabolism, and mitochondrial dysfunction in microglial and alveolar basal epithelial cells. *Cell Death Dis* 9: 245. <https://doi.org/10.1038/s41419-018-0280-z>

208. Yamashita S, Sato M, Matsumoto T, et al. (2018) Mechanisms of carnosine-induced activation of neuronal cells. *Biosci Biotechnol Biochem* 82: 683–688. <https://doi.org/10.1080/09168451.2017.1413325>

209. Kramarenko GG, Markova ED, Ivanova-Smolenskaya IA, et al. (2001) Peculiarities of carnosine metabolism in a patient with pronounced homocarnosinemia. *Bull Exp Biol Med* 132: 996–999. <https://doi.org/10.1023/a:1013687832424>

210. Bessman SP, Baldwin R (1962) Imidazole aminoaciduria in cerebromacular degeneration. *Science* 135: 789–791. <https://doi.org/10.1126/science.135.3506.789>

211. Levenson J, Lindahl-Kiessling K, Rayner S (1964) Carnosine excretion in juvenile amaurotic idiocy. *Lancet* 2: 756–757. [https://doi.org/10.1016/s0140-6736\(64\)92581-4](https://doi.org/10.1016/s0140-6736(64)92581-4)

212. Fonteh AN, Harrington RJ, Tsai A, et al. (2007) Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. *Amino Acids* 32: 213–224. <https://doi.org/10.1007/s00726-006-0409-8>

213. Chao de la Barca JM, Rondet-Courbis B, Ferré M, et al. (2020) A Plasma Metabolomic Profiling of Exudative Age-Related Macular Degeneration Showing Carnosine and Mitochondrial Deficiencies. *J Clin Med* 9: 631. <https://doi.org/10.3390/jcm9030631>

214. Balion CM, Benson C, Raina PS, et al. (2007) Brain type carnosinase in dementia: a pilot study. *BMC Neurol* 7: 38. <https://doi.org/10.1186/1471-2377-7-38>

215. Wassif WS, Sherwood RA, Amir A, et al. (1994) Serum carnosinase activities in central nervous system disorders. *Clin Chim Acta* 225: 57–64. [https://doi.org/10.1016/0009-8981\(94\)90027-2](https://doi.org/10.1016/0009-8981(94)90027-2)

216. Virani SS, Alonso A, Aparicio HJ, et al. (2021) Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. *Circulation* 143: e254–e743. <https://doi.org/10.1161/cir.0000000000000950>

217. Davis CK, Laud PJ, Bahor Z, et al. (2016) Systematic review and stratified meta-analysis of the efficacy of carnosine in animal models of ischemic stroke. *J Cereb Blood Flow Metab* 36: 1686–1694. <https://doi.org/10.1177/0271678x16658302>

218. Anderson NE, Broad JB, Bonita R (1995) Delays in hospital admission and investigation in acute stroke. *BMJ* 311: 162. <https://doi.org/10.1136/bmj.311.6998.162>

219. Stvolinsky S, Kukley M, Dobrota D, et al. (2000) Carnosine protects rats under global ischemia. *Brain Res Bull* 53: 445–448. [https://doi.org/10.1016/s0361-9230\(00\)00366-x](https://doi.org/10.1016/s0361-9230(00)00366-x)

220. Kopach O, Rusakov DA, Sylantyev S (2022) Multi-target action of β -alanine protects cerebellar tissue from ischemic damage. *Cell Death Dis* 13: 747. <https://doi.org/10.1038/s41419-022-05159-z>

221. Joshi P, Perni M, Limbocker R, et al. (2021) Two human metabolites rescue a *C. elegans* model of Alzheimer's disease via a cytosolic unfolded protein response. *Commun Biol* 4: 843. <https://doi.org/10.1038/s42003-021-02218-7>

222. Pulido A, Hulbert B, Giese H, et al. (2023) Copper Chelation via beta-alanine extends lifespan in a *C. elegans* model of Alzheimer's Disease. *Brain Disorders* 10: 100076. <https://doi.org/10.1016/j.dscb.2023.100076>

223. Javonillo DI, Tran KM, Phan J, et al. (2021) Systematic Phenotyping and Characterization of the 3xTg-AD Mouse Model of Alzheimer's Disease. *Front Neurosci* 15: 785276. <https://doi.org/10.3389/fnins.2021.785276>

224. Kulikova O, Troshev D, Berezhnoy D, et al. (2023) Neuroprotective Efficacy of a Nanomicellar Complex of Carnosine and Lipoic Acid in a Rat Model of Rotenone-Induced Parkinson's Disease. *Antioxidants (Basel)* 12: 1215. <https://doi.org/10.3390/antiox12061215>

225. Ali AN, Su L, Newton J, et al. (2025) Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study. *Nutrients* 17: 2130. <https://doi.org/10.3390/nu17132130>

226. Schilly KM, Gunawardhana SM, Wijesinghe MB, et al. (2020) Biological applications of microchip electrophoresis with amperometric detection: in vivo monitoring and cell analysis. *Anal Bioanal Chem* 412: 6101–6119. <https://doi.org/10.1007/s00216-020-02647-z>

227. Toviwek B, Koonawootrittriron S, Suwanasoppe T, et al. (2024) Why Bestatin Prefers Human Carnosinase 2 (CN2) to Human Carnosinase 1 (CN1). *J Phys Chem B* 128: 11876–11884. <https://doi.org/10.1021/acs.jpcb.4c05571>

228. Peppers SC, Lenney JF (1988) Bestatin inhibition of human tissue carnosinase, a non-specific cytosolic dipeptidase. *Biol Chem Hoppe Seyler* 369: 1281–1286. <https://doi.org/10.1515/bchm3.1988.369.2.1281>

229. Qiu J, Hauske SJ, Zhang S, et al. (2019) Identification and characterisation of carnostatine (SAN9812), a potent and selective carnosinase (CN1) inhibitor with in vivo activity. *Amino Acids* 51: 7–16. <https://doi.org/10.1007/s00726-018-2601-z>

230. Toviwek B, Suwanasoppe T, Koonawootrittriron S, et al. (2023) Binding Modes of Carnostatine, Homocarnosine, and Ophidine to Human Carnosinase 1. *ACS Omega* 8: 42966–42975. <https://doi.org/10.1021/acsomega.3c06139>

231. Vistoli G, Orioli M, Pedretti A, et al. (2009) Design, synthesis, and evaluation of carnosine derivatives as selective and efficient sequestering agents of cytotoxic reactive carbonyl species. *ChemMedChem* 4: 967–975. <https://doi.org/10.1002/cmdc.200800433>

232. Masuoka N, Yoshimine C, Hori M, et al. (2019) Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4. *Nutrients* 11: 1626. <https://doi.org/10.3390/nu11071626>

233. Szcześniak D, Budzeń S, Kopeć W, et al. (2014) Anserine and carnosine supplementation in the elderly: Effects on cognitive functioning and physical capacity. *Arch Gerontol Geriatr* 59: 485–490. <https://doi.org/10.1016/j.archger.2014.04.008>

234. Rokicki J, Li L, Imabayashi E, et al. (2015) Daily Carnosine and Anserine Supplementation Alters Verbal Episodic Memory and Resting State Network Connectivity in Healthy Elderly Adults. *Front Aging Neurosci* 7: 219. <https://doi.org/10.3389/fnagi.2015.00219>

235. Hisatsune T, Kaneko J, Kurashige H, et al. (2016) Effect of Anserine/Carnosine Supplementation on Verbal Episodic Memory in Elderly People. *J Alzheimers Dis* 50: 149–159. <https://doi.org/10.3233/jad-150767>

236. Katakura Y, Totsuka M, Imabayashi E, et al. (2017) Anserine/Carnosine Supplementation Suppresses the Expression of the Inflammatory Chemokine CCL24 in Peripheral Blood Mononuclear Cells from Elderly People. *Nutrients* 9: 1199. <https://doi.org/10.3390/nu9111199>

237. Ding Q, Tanigawa K, Kaneko J, et al. (2018) Anserine/Carnosine Supplementation Preserves Blood Flow in the Prefrontal Brain of Elderly People Carrying APOE e4. *Aging Dis* 9: 334–345. <https://doi.org/10.14336/ad.2017.0809>

238. Goto K, Maemura H, Takamatsu K, et al. (2011) Hormonal responses to resistance exercise after ingestion of carnosine and anserine. *J Strength Cond Res* 25: 398–405. <https://doi.org/10.1519/JSC.0b013e3181bac43c>



AIMS Press

© 2025 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>)